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Abstract
The five-membered pyrrolidine ring is one of the nitrogen heterocycles used widely 
by medicinal chemists to obtain compounds for the treatment of human diseases. 
The great interest in this saturated scaffold is enhanced by (1) the possibility to effi-
ciently explore the pharmacophore space due to  sp3-hybridization, (2) the contribu-
tion to the stereochemistry of the molecule, (3) and the increased three-dimensional 
(3D) coverage due to the non-planarity of the ring—a phenomenon called “pseu-
dorotation”. In this review, we report bioactive molecules with target selectivity 
characterized by the pyrrolidine ring and its derivatives, including pyrrolizines, pyr-
rolidine-2-one, pyrrolidine-2,5-diones and prolinol described in the literature from 
2015 to date. After a comparison of the physicochemical parameters of pyrrolidine 
with the parent aromatic pyrrole and cyclopentane, we investigate the influence of 
steric factors on biological activity, also describing the structure–activity relation-
ship (SAR) of the studied compounds. To aid the reader’s approach to reading the 
manuscript, we have planned the review on the basis of the synthetic strategies used: 
(1) ring construction from different cyclic or acyclic precursors, reporting the syn-
thesis and the reaction conditions, or (2) functionalization of preformed pyrrolidine 
rings, e.g., proline derivatives. Since one of the most significant features of the pyr-
rolidine ring is the stereogenicity of carbons, we highlight how the different stereoi-
somers and the spatial orientation of substituents can lead to a different biological 
profile of drug candidates, due to the different binding mode to enantioselective pro-
teins. We believe that this work can guide medicinal chemists to the best approach in 
the design of new pyrrolidine compounds with different biological profiles.
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Abbreviations
5-LOX  5-Lipoxygenase
A549  Lung cancer cell line
AChE  Acetylcholinesterase
AD  Alzheimer’s disease
AG  α-Glucosidase
ALR2  Aldose reductase
APP  Amyloid precursor protein




BACE1  Beta-secretase 1
BBB  Blood–brain barrier
BChE  Butyrylcholinesterase
BHK  Baby hamster kidney cell line
CAPAN-1  Pancreatic cancer cell line
Cas  Carbonic anhydrases
CC50  Concentration required to inhibit cell proliferation by 50%
CCRF-CEM  Acute lymphocytic leukemia
CNS  Central nervous system
COX-1  COX-2, cyclooxygenase-1, cyclooxygenase-2
DHFR  Dihydrofolate reductase
DNJ∙HCl  Deoxynojirimycin chlorohydrate
DOS  Diversity-oriented synthesis
DPP4  Dipeptidyl peptidase-4
α/γEC50  α/γ Half maximal effective concentration values
ED50  Median effective dose
ER  Efflux ratio
ER  Estrogen receptor
ES-2  Ovarian clear carcinoma cell
FAAH  Fatty acid amide hydrolase
FDA  Food and Drug Administration
FPA  Fluorescence polarization assay
FTase  Human protein farnesyltransferase
GI50  Growth inhibitory dose 50%
Glc-N-6P  Glucosamine-6-phospate synthase
GLP-1  Glucagon-like peptide-1
GlyT1  Glycine transporter-1
hCA I and II  Human isoenzymes I and II
HDAC2  Histone deacetylase 2
HeLa  Cervix carcinoma
hGLYT1  Human glycine transporter-1
IC50  Half maximal inhibitory concentration value
K562  Chronic myeloid leukaemia cell line
KIT  Tyrosine-protein kinase KIT
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MBH  Morita–Baylis–Hillman
Mcl-1  Myeloid cell leukemia-1
MCF-7  Breast cancer cell line
MDA-MB-436  Breast carcinoma cell line
MES  Maximal electroshock
MMP-2  -9, Matrix metalloproteinases 2, -9
NAAA  N-Acylethanolamine acid amidase
NBS  N-Bromosuccinimide
NCI  National Cancer Institute
NCI-H522  Non-small cell lung cancer
NMDA  N-Methyl-d-aspartate
NP  Natural product
PARP-1-2  Poly(ADP-ribose) polymerase-1, -2
PXR  Pregnane X receptor
PC-3  Prostatic cancer cell line
PDB ID  Protein data bank identification
P-gp  P-glycoprotein
PHB2  Prohibitin 2
PK  Pharmacokinetics
PPARs  Peroxisome proliferator-activated receptors
P-tau  Tau protein
RORγt  Retinoic acid-related orphan receptor γ
SAR  Structure–activity relationship
SARMs  Selective androgen receptor modulators
scPTZ  Subcutaneous pentylenetetrazole
SI  Selectivity index
VDCCs  Voltage-gated calcium channels
VGSCs  Voltage-gated sodium channels
VPA  Valproic acid
1 Introduction
The development of clinically active drugs relies increasingly on the use of hetero-
cyclic scaffolds, many of which contain nitrogen, as evidenced by the considerable 
number of bioactive compounds now available [1–5]. The introduction of hetero-
atomic fragments in these molecules is not a random choice, considering that they 
are useful tools for modifying physicochemical parameters and obtaining the best 
ADME/Tox results for drug candidates [6, 7]. Although two-dimensional (2D) flat 
heteroaromatic ring scaffolds are used widely by medicinal chemists, due mainly to 
their easy structural modification [8, 9], heteroatomic saturated ring systems allow 
a greater chance of generating structural diversity [10]. This molecular complexity 
was defined by Lovering et al. [11] through two descriptors, the  sp3-hybridization 
and number of chiral centers, both of which are essential for establishing the clinical 
success of new bioactive molecules. Indeed, the chemical complexity and the globu-
lar three-dimensional (3D) shape offer more opportunities to improve druggability 
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by modifying parameters such as solubility, lipophilicity, and other ADME prop-
erties [12]. This association was also highlighted by Ritchie et  al. [13] who con-
ducted an interesting study on a set of 19,196 molecules containing three rings with 
different degrees of aromaticity. Molecules with growing hetero-aliphatic character 
showed an increase in aqueous solubility compared with those comprising three 
aromatic rings. Thus, each portion of the molecules can potentially influence the 
balance of the physicochemical parameters, which needs to be considered when 
designing compounds with an optimized pharmacokinetic (PK) profile. Table  1 
summarizes a comparison of some of the molecular descriptors and parameters of 
the pyrrolidine nucleus with that of carbocyclic cyclopentane and aromatic pyrrole. 
As shown in Table 1, the presence of the nitrogen atom contributes to the polarity 
of the molecules, producing a dipole moment (D) and a marked PSA value, which 
cyclopentane lacks. Although both, pyrrole and pyrrolidine, show similar polar sur-
face area (PSA) values, only the  pKBHX values (pyrrole = 0.15, pyrrolidine = 2.59) 
take into account the strength of the H-bonds. The presence of nitrogen also affects 
the lipophilicity of the heterocyclic rings, as evidenced by the lower LogP values of 
pyrrolidine and pyrrole, and the solvent accessible surface area (SASA) FISA and 
FOSA values. Also interesting is the CI_logS value of pyrrole, which is different 
from the LogS, highlighting how the planarity of the aromatic ring can influence 
aqueous solubility.
Over the past two decades, much effort have been made by industry to provide 
the chemistry community with new  sp3-enriched 3D building blocks as commercial 
sources from which to produce molecules relevant from a medicinal chemistry point 
of view. In this context, Goldberg et al. [14] from AstraZeneca shed light on “design 
guidelines and strategic goals when designing novel reagents for drug discovery pro-
jects”, and the 3D shape appears as one of the strategic goals for the design of rea-
gents for drug discovery programs. The 3D shapes of the non-aromatic pyrrolidine 
and cyclopentane rings with the aromatic pyrrole ring are compared in Fig. 1. The 
different bond angles and lengths clearly suggest the flatness of the 2D structure of 
pyrrole and the 3D coverage of pyrrolidine and cyclopentane.
A statistical analysis conducted by Tajabadi et  al. [15] found that 70% of the 
15,822 scaffolds belonging to natural products (NPs) are non-flat and represent an 
interesting resource for the design of new synthetic molecules [16]. Among such 
saturated ring systems, the pyrrolidine moiety is represented widely in NPs, espe-
cially in alkaloids isolated from plants or microorganisms [17–19] (Fig.  2) show-
ing different biological activities, e.g. nicotine 1 (antioxidant, anti-inflammatory, 
antihyperglycemic properties), scalusamides A 2 and (R)-bgugaine 3  (antimicro-
bial, antifungal properties), 1,4-dideoxy-1,4-imino-d-ribitol 4 and aegyptolidine A 5 
(anticancer properties). Therefore, it is no coincidence that the pyrrolidine nucleus is 
among the most preferred scaffolds in pharmaceutical science and drug design [20], 
as evidenced by the fact that it ranks first among the top five most common five-
membered non-aromatic nitrogen heterocycles, appearing in 37 drugs approved by 
the United States (US) Food and Drug Administration (FDA) [21]. Moreover, pyr-
rolidine and its derivatives are used widely as ligands for transition metals, organo-
catalysts, and effective chiral controllers in asymmetric synthesis [22–24].
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N(1)-C(2) 1.47 1.37 - 
C(1)-C(2) - - 1.53 
C(2)-C(3) 1.51 1.38 1.52 
C(3)-C(4) 1.51 1.42 1.52 
C(4)-C(5) 1.52 1.38 1.52 
C(5)-N(1) 1.47 1.37 - 
C(5)-C(1) - - 1.53 
Bond Angle (Å) 
C(2)-N(1)-C(5) 107.63 109.33 - 
C(2)-C(1)-C(5) - - 103.63 
N(1)-C(2)-C(3) 105.54 108.00 - 
C(1)-C(2)-C(3) - - 105.74 
C(2)-C(3)-C(4) 102.26 107.34 106.30 
C(3)-C(4)-C(5) 103.13 107.33 104.90 
C(4)-C(5)-N(1) 106.83 108.00 - 
C(4)-C(5)-C(1) - - 102.95 
Pyrrolidine Pyrrole Cyclopentane 
Bond Length (Å) 
Fig. 1  Comparison of the three-dimensional (3D) shape of the non-aromatic pyrrolidine and cyclopen-
tane rings with the aromatic pyrrole ring. Bond angles, bond lengths, and MMFF94 values were calcu-


































Fig. 2  Representative structures of natural alkaloids 1–5 
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The great interest in the pyrrolidine scaffold has allowed chemists to explore new 
methods for its synthesis, thus bypassing conventional approaches. The application 
of microwave-assisted organic synthesis (MAOS) for the synthesis of pyrrolidines 
has had a strong impact, allowing synthetic efficiency to be increased, and also sup-
porting the new era of green chemistry [25].
In this review, we highlight the interest of the chemistry community in pyrro-
lidine and its derivatives, including pyrrolizines, pyrrolidine-2-one, pyrrolidine-
2,5-diones, and prolinol, incorporated in bioactive molecules with target selectiv-
ity published from 2015 to date. We have organized the review on the basis of the 
synthetic approach used: (1) construction of the ring from different cyclic or acyclic 
precursors, and (2) functionalization of preformed pyrrolidine rings, e.g., proline 
derivatives.
2  Influence of Steric Factors on Biological Activity
Contrary to the parent aromatic compound pyrrole, which is a common scaffold of 
several bioactive compounds [26–28], the great interest in synthetic pyrrolidines is 
also due to the presence of up to four stereogenic carbon atoms leading to up to 16 
different stereoisomers [29]. In this regard, the non-essential amino acid l-proline, 
with one chiral center, is frequently employed as a building block to produce chiral 
compounds, and as a catalyst for successful stereoselective synthesis [30, 31]. Since 
proteins are enantioselective, the introduction of chiral centers would represent a 
purposive strategy for the generation of selective ligands. Moreover, knowing the 
absolute and relative configuration of chiral centers can allow the toxicity or inactiv-
ity of one of the enantiomers to be avoided, a concept regulated extensively by US 
FDA guidelines on the “Development of new stereoisomeric drugs” [32]. In contrast 
to the pyrrole ring, thanks to “pseudorotation”, an intrinsic property of saturated 
five-membered rings, pyrrolidines gain energetically advantageous conformations 
offering interesting 3D coverings [33]—a useful tool for the exploration of phar-
macophore space via diversity-oriented synthesis (DOS) [34, 35]. Overall, based 
on the electronegativity of C-4 substituents, the pyrrolidine ring of proline acquires 
two specific conformations called C-4 (or Cγ) -exo and -endo envelope conformers. 
This means that puckering of the ring can be controlled easily through inductive 
Fig. 3  Exo and endo conformers of trans- and cis-4-fluoroproline 6 and 7, respectively; trans/cis-4-fluo-
roproline 8 resulting from the superimposition of structures 6 and 7 
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and stereoelectronic factors. For instance, in the case of l-proline, the endo con-
former is preferred, whereas trans-4-fluoroproline 6 and cis-4-fluoroproline 7 favor 
the exo and endo envelope conformation, respectively (Fig. 3). The overlap of trans/
cis-4-fluoroproline 8 clearly shows the different folding of the molecules induced by 
the R or S configuration of the carbon bearing the fluorine atom. Conversely, C-4 
alkylation of proline with a methyl or tert-butyl group is used to lock the opposite 
conformation [36].
2.1  The Enantiopure Compound Shows Full Agonism Towards G‑Protein Coupled 
Receptor 40
Notably, Jurica et  al. [37] synthesized a series of G-protein coupled receptor 40 
(GRP40) agonists, like compounds (R,R)-9 and (S,S)-9, for the treatment of type 2 
diabetes (Fig. 4). They demonstrated that a cis-4-CF3 substituent on the pyrrolidine 
scaffold favors the pseudo-axial conformation of the groups in the other positions, as 
evaluated for the acetic acid group at position 2, which is the main pharmacophore 
for GRP40 agonists. By lead optimization, they observed that the enantiopure (R,R)-
9 derivative displayed full agonism, both in human GRP40 (hGRP40, 0.11 µM) and 
mouse GRP40 (mGRP40, 0.054 µM) due to the different binding mode compared 
to its enantiomer (S,S)-9 (hGRP40 0.49 µM and mGRP40 2.4 µM), in addition to 
a better in vivo profile in lowering glucose plasma levels in mice tested in the oral 
glucose tolerance test at 0.3 or 1 mg   kg−1 doses, and a dual mechanism of action 
including glucose-dependent insulin and GLP-1 secretion in vitro.
2.2  The New Spatial Arrangement in the Crystallized Ligand–Protein Complex 
Promotes Selectivity for CK1γ
The role of steric factors was also investigated by Luxenburger et al. [38], who syn-
thesized potent and selective CK1 kinase inhibitors exhibiting a chiral pyrrolidine 
scaffold, functionalizing the CK1γ inhibitor derivative 10 (Fig.  4). Interestingly, 
the new enantiopure hydroxyl-functionalized pyrrolidine derivatives 11a–b (Fig. 4) 
showed selectivity for CK1 in the enzyme assay against a panel of 320 different 
kinases. To investigate the binding mode of the chiral moiety, X-ray crystallog-
raphy was conducted. The crystal structure showed that, due to the incorporation 
of a methylene group through a spontaneously Pictet-Spengler cyclization, two 
new ligands (compounds 12a,b) (Fig.  4) were formed. These compounds showed 
nanomolar activity against CK1γ and CK1ε (0.011 and 0.056 µM, and 0.024 and 
0.196 µM, respectively), thus suggesting that further modifications should be made 
to investigate how the chiral moiety influences kinase inhibition.
2.3  The Orientation of 3‑R‑Methylpyrrolidine is Responsible for a Pure Estrogen 
Receptor α Antagonist and Selective ER Degrader
In 2018, through biochemical and biophysical assays, coupled with high-resolution 
X-ray crystal structures, Fanning et al. [39] provided a molecular explanation of how 
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Fig. 4  Stereospecific pyrrolidine derivatives (R,R)-9, (S,S)-9, 11a,b, 12a,b, 13a,b, and 14 
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the stereospecific orientation can change the binding mode of antiestrogen benzo-
pyran derivatives 13a,b and 14 (Fig.  4) within the hormone-binding pocket. Spe-
cifically, they showed that the orientation of 3-R-methylpyrrolidine 13a was respon-
sible for the compound being a pure ERα (estrogen receptor α) antagonist and a 
selective ER degrader (PA-SERD) for the treatment of breast cancer, opposite to the 
3-S-methylpyrrolidine 13b and the unsubstituted derivative 14. This is due to the 
capability of the R-methyl group of compound 13a to increase the mobility in the 
loop connecting helices 11 and 12 (H11–12 loop) of the ERα protein.
2.4  Introduction of a Cis‑3,4‑Diphenylpyrrolidine Moiety Provides a Potent 
Inverse Agonist of RORγt
Recently, Jiang et  al. [40] demonstrated that replacing a non-stereochemical with 
a stereochemical group was beneficial for the activity of a new series of cis-3,4-di-
phenylpyrrolidine derivatives as inverse agonists of the retinoic acid-related orphan 
receptor γ (RORγt)—a splice variant of the nuclear hormone receptor subfamily 
RORγ involved in autoimmune diseases. The design of the new molecules started 
by studying the binding conformation of bicyclic sulfonamide 15 (Fig.  5), which 
showed excellent potency towards RORγt (12  nM) but suffered from undesirable 
activity against pregnane X receptor (PXR,  EC50 = 144  nM, Ymax = 100%),  which 
upregulates proteins involved in the detoxification and clearance of foreign toxic 
substances from the body. In the X-ray co-crystal structure of compound 15 in 
























Fig. 5  Structures of retinoic acid-related orphan receptor γ (RORγt) ligands 15 and its RORγt binding 
conformation (top right) [40] as well as 16 
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benzothiazine moiety, while the folding of the para-F-phenyl ring creates face-to-
face pi stacking interactions with the benzene ring of the benzothiazine moiety, as 
shown in the upper panel of Fig. 5. This “U-shaped” conformation was maintained 
by replacing the sulphonyl group with the cis-3,4-diphenylpyrrolidine scaffold. 
Lead optimization led to piperidinyl carboxamide 16 (Fig. 5), which proved a bal-
ance between potency against RORγt with an  EC50 of 61  nM and a considerably 
lower PXR activity  (EC50 = 495, Ymax = 46%). Remarkably, (1) the cis-configuration 
accommodates the two phenyl rings close to the face-to-face stacked arrangement, 
(2) the hexafluoroisopropyl alcohol moiety establishes a hydrogen bonding interac-
tion between the hydroxy group and His479 of RORγt, (3) transposition of the C3 
methyl group in C4 position leads to the loss of RORγt potency. In addition, (4) pyr-
rolidines with an unsubstituted nitrogen were weak agonists compared with tertiary 
amines, and (5) a para-F substituent in the 3-phenyl ring improved  EC50 values.
2.5  Basicity and Nucleophilicity of the Pyrrolidine Nucleus
While substituents at C-4 of proline affect the puckering of the ring, substituents 
at C-2 of pyrrolidine shift its basicity. In fact, the nitrogen atom of pyrrolidine, as 
a secondary amine, confers basicity to the scaffold. In this context, An et al. [41] 
investigated the basicity of a set of 28 pyrrolidines used as organocatalysts, showing 
that particularly charged substituents have a strong effect on the basicity. Lastly, due 
to its nucleophilicity, the pyrrolidine nitrogen represents a privileged position for 
substitutions, with 92% of all US FDA approved pyrrolidine drugs being substituted 
at the N −1 position [21].
2.6  Spatial Characteristics Influencing the Biological Activities of Pyrrolidine 
Derivatives
In summary, the advantages of using the pyrrolidine scaffold in drug design are due 
to the unrestricted conformation of the ring, which can be controlled and locked by 
the appropriate choice of substituents. Indeed, inductive and stereoelectronic factors 
influence the puckering of the pyrrolidine ring and, consequently, its pharmacologi-
cal efficacy. The following list summarizes the spatial dispositions of the pyrroli-
dine scaffold that affect the biological activity towards specific targets cited in this 
chapter:
• cis-4-CF3 substituent on the pyrrolidine scaffold endorses the pseudo-axial con-
formation of the groups in the other positions, leading compounds able of show-
ing full agonism in both the human and mice GRP40 receptor;
• compared with 3-S-methylpyrrolidine or an unsubstituted pyrrolidine, 3-R-meth-
ylpyrrolidine promotes a pure ERα antagonist and selective ER degrader (PA-
SERD) for the treatment of breast cancer;
• the introduction of a chiral pyrrolidine into molecules promotes selectiv-
ity towards CK1 receptors. However, the selectivity and potency for the CK1γ 
 Topics in Current Chemistry          (2021) 379:34 
1 3
  34  Page 12 of 46
isoform is due to the methylene group at position 2 being involved in sponta-
neous intramolecular Pictet–Splenger cyclization during crystallization with the 
protein;
• a cis-3,4-diphenylpyrrolidine scaffold gives the molecule a “U-shape” conforma-
tion that is beneficial for inverse agonistic activity on the RORγt receptor.
3  Pyrrolidine Derivatives Obtained by Ring Synthesis
3.1  Pyrrolidines Obtained by 1,3‑Dipolar Cycloadditions
A classical method for the preparation of five-membered heterocycles is the 
1,3-dipolar cycloaddition [42] between a 1,3-dipole, such as a nitrone, an azide or 
an azomethine ylide, with a dipolarophile, typically an olefin, both of which are 
responsible for the regio- and stereoselectivity of the reaction [29, 43]. In particular, 
for synthetic pyrrolidines, the 1,3-dipolar cycloaddition reaction between nitrogen-
based 1,3-dipole azomethine ylides with alkenyl dipolarophiles has been studied 
extensively. As shown in Fig. 6, stereoselectivity at positions 2 and 5  (R1 and  R2) 
depends on the shape of the ylides, whereas stereochemistry in positions 3 and 4 
correlates with the relative orientation of the substituents of the dipolarophile, lead-
ing to 3,4-cis- or 3,4-trans-substituted pyrrolidines [44].
Exploiting the 1,3-dipolar cycloaddition process between N-(methoxymethyl)-
N-(trimethylsilylmethyl)benzylamine 17 and methyl acrylate 18 (Fig. 7) under acid 
conditions in the presence of trifluoroacetic acid (TFA), Min et al. [45] synthesized 
a series of benzimidazole carboxamides 19a–p bearing the pyrrolidine nucleus at 
position 2. In particular, they functionalized the pyrrolidine nitrogen by introducing 

























































Fig. 6.  1,3-Dipolar cycloadditions to stereoselectively obtain pyrrolidine derivatives
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polymerase-1 and -2 (PARP-1,-2), enzymes involved in the DNA damage repair pro-
cess, as depicted in Fig. 7.
Out of 16 compounds, 6, namely 19c,h–j,o,p, inhibited PARP-1 and -2 with  IC50 
values ≤10  nM. Structure–activity relationship (SAR) analysis revealed that the 
length of the alkyl chain and the presence of the carbonyl group greatly influence 
biological activity. Overall, the most promising derivatives were the phenyl ketone 
derivatives 19c,i,j,p, rather than the N-phenylamine 19h or the N-benzamide 19o 
derivatives. Comparing the activity within the entire class of phenyl ketone deriva-
tives bearing 2–4 carbon atoms in the alkyl chain (19c,d,i,j,p), compounds 19i,j,p 
with the 3-carbon atom chain were the most active. Docking studies highlighted that 
the phenyl ketone fragments of compounds 19j and 19p would bind the three impor-


























19a -CH2(CO)NH-phenyl 17.6 34.5 / /
19b -(CH2)2(CO)NH-phenyl 19.9 41.2 / /
19c -(CH2)3(CO)-phenyl 42.8 62.3 12.2 5.8
19d -CH2(CO)-phenyl -1.1 7.2 / /
19e -(CH2)3-N-isatin 22.0 74.5 / /
19f -CH2CH(OH)-phenyl 5.0 9.0 / /
19g -(CH2)2CH(OH)-phenyl -2.1 6.5 / /
19h -(CH2)3NH-phenyl 47.5 66.2 7.1 3.3
19i -(CH2)2(CO)-phenyl-4-OCH3 59.2 62.5 5.9 4.5
19j -(CH2)2(CO)-phenyl-4-Cl 65.7 65.6 3.9 4.2
19k -(CH2)2-N-isatin 6.0 37.1 / /
19l -(CH2)3-NH2 26.8 46.4 / /
19m -(CH2)2-NH2 24.8 32.8 / /
19n -(CH2)3-NH-(CO)-phenyl 19.4 39.1 / /
19o -(CH2)2-NH-(CO)-phenyl 38.4 66.2 11.1 5.7
19p -(CH2)2(CO)-phenyl 68.0 76.7 3.6 3.2
Veliparib / 63.7 78.3 5.3 1.6
Fig. 7  General synthetic scheme to benzimidazole carboxamides 19a–p. R substituents and 
poly(adenosine 5′-diphosphate (ADP)-ribose) polymerase (PARPs) inhibition assay of compounds 19a–
p. PARP-1 and -2 inhibition (%) were evaluated at 10 nM. Reagents and conditions: a trifluoroacetic acid 
(TFA), dichloromethane (DCM), 17 h, room temperature (r.t.), yield: 96%
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Gly-863 and Ser-904 as in compounds 19c and 19d. Additionally, Van der Waals or 
hydrophobic interactions between the side chain of the compounds and the residues 
in the active site of PARP-1 were thought to facilitate the binding of these benzimi-
dazole carboxamides. Electron donating or withdrawing groups in the para position 
of the benzene ring, as in compounds 19i and 19j, caused inhibitory activity similar 
to the reference compound veliparib, but with slightly higher  IC50 values compared 
with the unsubstituted derivative 19p. Reduction of the carbonyl group to a hydroxy 
group (19f and 19g), the presence of hydrophilic amine chains (19l and 19m), or 
the bulky phthalimide group (19e and 19k), were detrimental for enzymatic inhibi-
tion. Cytotoxic assays against MDA-MB-436 (breast cancer) and CAPAN-1 (pan-
creatic cancer) cell lines confirmed 19j as the most promising compound  (IC50 17.4 
and 11.4 µM, respectively), followed by 19p  (IC50 19.8 and 15.5 µM, respectively), 
which had  IC50 values much lower than those of the reference compounds olapa-
rib  (IC50 30.2 and 100 µM, respectively, in MDA-MB-436 and CAPAN-1 cells) and 
veliparib  (IC50 100 µM in both cell lines).
The same dipolar reagent N-(methoxymethyl)-N-(trimethylsilylmethyl)ben-
zylamine 17 was reacted with the nitrovinyl substrate 20, methyl trans-4-fluorocin-
namate 21, and chalcone 22, in the presence of a catalytic amount of TFA, by Wang 
et al. [46] to synthesize 3,4-disubstituted pyrrolidine sulfonamides 23a–y, 23z–ac, 
and 23ad, respectively (Fig. 8). All compounds were prepared as enantiomerically 
pure trans isomers and tested as selective glycine transporter-1 (GlyT1) competi-
tive inhibitors. The major role of GlyT1 is to maintain glycine concentration below 
saturation level at the postsynaptic ionotropic glutaminergic N-methyl-d-aspartate 
(NMDA) receptor. Since the aetiology of schizophrenia has been linked to impaired 
glutamatergic neurotransmission involving the NMDA receptor, the development of 
GlyT1 inhibitors may represent a putative treatment for it and other disorders associ-
ated with NMDA receptor hypofunction. The new pyrrolidine sulfonamides 23a–ad 
were synthesized based on the SAR investigation conducted on the reference com-
pound 23a. The latter displayed satisfactory GlyT1 inhibitory potency in vitro, with 
a Ki value of 0.198 µM, but a high efflux ratio (ER) of 8.7, indicating it as potential 
substrate of P-glycoprotein (P-gp)—the most relevant efflux transporter expressed 
in blood–brain barrier (BBB). The transformation of the sulfonamide moiety into 
amides, carbamides, tertiary amines, and urea groups, including the pyrrolidine 
nitrogen, produced inactive inhibitors of GlyT1 (structures not shown). The replace-
ment of the benzoyl group of compound 23a by aryl substituents  (R2) gave excellent 
outcomes, providing new potent analogues such as 23d,f–i,k,l,o–t,y,z with single or 
double digit nanomolar activity. Among these, the anilines 23d,g–i,k,l,o,p,s,v,x also 
exhibited lower ER values and consequently less susceptibility to P-gp efflux. Com-
parable in vitro potency and ER values were obtained when replacing the 1-meth-
ylimidazole moiety by a 1-methyl-1,2,3-triazole substituent obtaining compound 
23u, which proved metabolically unstable. As reported in Fig. 8, the fluorophenyl 
substituents at position 3  (R1) of the pyrrolidine sulfonamides offered better in vitro 
potency and ER profile, followed by the unsubstituted phenyl ring (23b–f). Concern-
ing  R2 substituents, meta-substituted derivatives showed improved biological activ-
ity. Instead, the activity of compounds with heteroaromatic substituents in position 4 
(23j,m,q,r) was influenced by the number and position of the nitrogen atoms of the 
1 3
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heteroaromatic, as shown in Fig. 8. Finally, the analogue 23t  (R2 = indanyl) showed 
the best balance between potency and ER value (Ki = 0.001 μM, ER = 1.5).
1,3-Dipolar cycloadditions between N-(methoxymethyl)-N-(trimethylsilylmethyl)
benzylamine 17 and cis- or trans-alkenyl ester derivatives 24 (Fig. 9) in TFA, were 
used by Zhang et  al. [47] to gain a series of 4-benzylpyrrolidine-3-carboxylic 
acid derivatives as potent agonists at peroxisome proliferator-activated receptors 
(PPARs). Among the new pyrrolidines, the cis-3R,4S-configured compounds 25 






















































23b phenyl phenyl 1-CH3-1H-imidazol-4-yl 0.9 0.199
23c phenyl 2-CH3-phenyl 1-CH3-1H-imidazol-4-yl 1.3 1.51
23d phenyl 3-CH3-phenyl 1-CH3-1H-imidazol-4-yl 0.9 0.018
23e phenyl 4-CH3-phenyl 1-CH3-1H-imidazol-4-yl 0.6 1.25
23f phenyl 3-CF3-phenyl 1-CH3-1H-imidazol-4-yl - 0.008
23g 4-F-phenyl 3-CF3-phenyl 1-CH3-1H-imidazol-4-yl 0.9 0.003
23h 4-F-phenyl 3-Cl-phenyl 1-CH3-1H-imidazol-4-yl 1.1 0.003
23i 4-F-phenyl 3-CF3,4-F-phenyl 1-CH3-1H-imidazol-4-yl 0.8 0.005
23j 4-F-phenyl 5-CF3-pyridin-3-yl 1-CH3-1H-imidazol-4-yl 10 1.16
Fig. 8  General synthetic scheme to pyrrolidine sulfonamides 23a–ad. ER Efflux ratio values. Ki values 
towards hGLYT1 [46]. Reagents and conditions: a TFA (catalyst), DCM, r.t., overnight
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metabolism and ameliorating dyslipidaemia associated with type 2 diabetes. Com-
pounds 25 and 26 displayed αEC50 and γEC50 values in the low nanomolar range 
(5–90 nM). In addition, compound 26 was efficient in lowering fasting glucose and 
triglyceride levels in diabetic db/db mice after oral administration of a 10  mg/kg 
dose once daily. SAR studies revealed that (1) the oxybenzyl pyrrolidine acid series 
offered the best balance of PPARα/γ functional activities, (2) the cis-configuration 
of the substituents in positions 3 and 4 of the pyrrolidine ring was preferred over the 
trans orientation, and (3) N-carbamoyl and N-aryl-substituted oxybenzyl pyrrolidine 
acid analogs provided potent balanced PPARα/γ dual agonists.
Conjugated systems with biological macromolecules, including carbohydrates, 
lipids, proteins, and nucleic acids, require that special attention is paid to the geom-
etry of the molecules to be combined. Unlike the pyrrolidine scaffold, spiro-pyr-
rolidine molecules have rigid conformations that allow for easy incorporation into 
biological macromolecules, including cholesterol. For this purpose, Periyasami 
et al. [48] synthesized a small set of novel spiro-pyrrolidine/pyrrolizines by one-pot 
three-component reactions. Stereo- and regioselective reactions based on 1,3-dipo-
lar cycloaddition between the dipolarophile C3-β-cholesterolacrylate 27 (Fig.  9) 
under reflux in iPrOH for 2  h with azomethidine ylides, in turn generated in  situ 
by reaction isatin, acenaphthoquinone, or ninhydrine with the secondary amino 
acids sarcosine or proline, allowed the desired compounds to be obtained as sin-
gle isomers. All compounds were evaluated for their in vitro antibacterial activity 
23k 3-F-phenyl 3-Cl-phenyl 1-CH3-1H-imidazol-4-yl 1 0.042
23l 2-F-phenyl 3-Cl-phenyl 1-CH3-1H-imidazol-4-yl 0.9 0.021
23m 4-F-phenyl 2-CF3-pyridin-4-yl 1-CH3-1H-imidazol-4-yl 18.5 0.118
23n pyridin-3yl 3-CF3-phenyl 1-CH3-1H-imidazol-4-yl - 0.766
23o 4-F-phenyl 3-CF3-phenyl 1-CH3-1H-imidazol-4-yl 0.8 0.002
23p 4-F-phenyl 3-OCF3-phenyl 1-CH3-1H-imidazol-4-yl 0.7 0.004
23q 4-F-phenyl 4-CF3-pyridin-2-yl 1-CH3-1H-imidazol-4-yl 1.3 0.008
23r 4-F-phenyl 6-CF3-pyrimidin-4-yl 1-CH3-1H-imidazol-4-yl 7.5 0.005
23s 4-F-phenyl 3-OCF3,4-F-phenyl 1-CH3-1H-imidazol-4-yl 0.7 0.002
23t 4-F-phenyl 2,3-dihydro-1H-inden-1-yl 1-CH3-1H-imidazol-4-yl 1.5 0.001
23u 4-F-phenyl 3-CF3,4-F-phenyl 1-CH3-1H-1,2,3-triazole-4-yl 0.5 0.003
23v (R)-
esahydro-2H-pyran-2-yl
3-OCF3-phenyl 1-CH3-1H-imidazol-4-yl 0.8 0.003
23w (S)-tetrahydro-2H-furan-2yl 3-OCF3-phenyl 1-CH3-1H-imidazol-4-yl - 0.024
23x 1,3-dioxepan-2-yl 3-OCF3-phenyl 1-CH3-1H-imidazol-4-yl 0.9 0.002
23y 1,3-dioxan-2-y 3-OCF3-phenyl 1-CH3-1H-imidazol-4-yl 1.1 0.002
23z 4-F-phenyl 3-OCF3-phenoxymethyl 1-CH3-1H-imidazol-4-yl - 0.007







23ad phenyl benzyl 1-CH3-1H-imidazol-4-yl 1.3 0.093
Fig. 8  (continued)
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24a: X = CO-Xc(D) (Xc-(D)) = 
D-camphorsultam





25: R = -(CO)O-phenyl
αEC50 = 5 nM; γEC50 = 30 nM;
26: R = 3-CF3-pyrimidine










































Fig. 9.  1,3-Dipolar cycloadditions to yield 4-benzylpyrrolidine-3-carboxylic acids 25 and 26, synthesis 
of cholesterol-conjugated spiro-pyrrolidine/pyrrolizines 28–30, and 3D/2D interaction diagrams of com-
pound 28 with the active site of target receptor protein 1XFF [48]. Reagents and conditions: a TFA (1 M 
solution in DCM); b isopropyl alcohol (iPrOH), 2 h, under reflux, yields: 76% (28), 67% (29), 63% (30)
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against a panel of four human pathogens, including Vibrio cholerae, Proteus mira-
bilis, Micrococcus luteus, and Bacillus subtilis. The most active were compounds 
28, 29, and 30 (Fig.  9), which showed good antimicrobial activity, causing zones 
of growth inhibition in the performed disc diffusion assays ranging from 13.0 to 
15.1  mm, at 50  µg/ml. With the aim of investigating their biological potential as 
glucosamine-6-phospate synthase (Glc-N-6P) inhibitors, the authors performed 
in silico molecular docking studies with compounds 28–30 in the enzyme’s active 
site (PDB ID: 1XFF). The results showed significant interactions with active site 
amino acids, revealing that the spiropyrrolidine moiety of compound 28 is engaged 
in two H-bond interactions involving its –NH and –CO groups with those of the 
aliphatic nonpolar amino acid Gly78 (Fig. 9), thus demonstrating its prominent role 
in the inhibition of Glc-N-6-P synthase and thus in the antibacterial activity of the 
compounds.
By a one-pot multicomponent approach, Shyamsivappan et al. [49] synthesized 
phenyl/thiophene dispiro indenoquinoxaline pyrrolidine quinolone analogues, 36a–f 
and 37a–f (Fig. 10), via 1,3-dipolar cycloaddition reaction of (E)-3arylidine-8-nitro-
2,3-dihydroquinolin-4(1H)-ones 33a–f, ninhydrin 31, o-phenylenediamine 32 and 
benzylamine 34/thiophene methylamine 35 in MeOH under reflux for 2–3  h. All 
compounds were screened for anticancer activity against MCF-7 and HeLa cells, 

















































Fig. 10.  1,3-Dipolar cycloadditions to yield phenyl/thiophene dispiro indenoquinoxaline pyrrolidine 
quinolone derivatives 36a–f and 37a–f. Reagents and conditions: a MeOH, under reflux, 2–3 h, yields: 
92–98% (36a–f) and 93–96% (37a–f)
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19  µM, respectively, comparable to those of the reference compound doxorubicin 
(16 and 18 µM against MCF-7 and HeLa cells, respectively). Overall, the thiophen-
containing derivatives 37a–f showed better activity against both cell lines  (IC50 in 
the range of 17 and 28 µM against MCF-7, and 19 and 30 µM against HeLa) than 
their respective counterparts bearing the phenyl ring 36a–f  (IC50 in the range of 22 
and 29 µM against MCF-7; and 26 and 37 µM against HeLa). SAR analysis indi-
cated that compounds 36e,f, and 37e,f, characterized by electron donating groups, 
such as methoxy and methyl had lower  IC50 values than other derivatives with elec-
tron-withdrawing groups (EWGs). Further investigation into the mechanism behind 
the anticancer activity revealed that compound 37e induced apoptosis through intra-
cellular reactive oxygen species (ROS)-mediated caspase-3 activation.
3.2  Pyrrolidines Obtained by Pictet–Spengler‑Oxidative Ring Contractions
Moreover, spirocyclic motifs are emerging as an interesting feature for building 
block with low-molecular weight in the drug discovery field [50]. In 2016, Hati et al. 
[51] designed and synthesized a library of spiro[pyrrolidine-3,3′-oxindoles] 38a–n 
(Fig. 11) as potential anti breast cancer agents with a dual activity against histone 
deacetylase 2 (HDAC2) and prohibitin 2 (PHB2) enzymes. HDAC2 is responsible 
for the deacetylation of lysine residues on the N-terminal part of core histones (H2A, 
H2B, H3 and H4) and provides a tag for epigenetic repression, thus playing a sig-
nificant role in transcriptional regulation, cell cycle progression, and developmental 
events. PHB2 acts as a mediator of transcriptional repression by nuclear hormone 
receptors via recruitment of histone deacetylases and works like an ER-selective co-
regulator, potentiating the inhibitory activities of anti-estrogens and repressing the 
activity of estrogens. Based on the DOS strategy, the new compounds 38a–n were 
synthesized via a one-pot Pictet Spengler-oxidative ring contraction of tryptamine, 
in the presence of water as reactant, mediated by stoichiometric N-bromosuccinim-
ide (NBS) as oxidant, and a catalytic amount of TFA, varying the aromatic function-
















38a: Ar = 3-CH3-phenyl
38b: Ar = 3,5-diCH3-phenyl
38c: Ar = 2,6-diF-phenyl
38d: Ar = 3-F-phenyl
38e: Ar = 3-OCH3-phenyl
38f: Ar = 3,4-diOCH3-phenyl
38g: Ar = 4-OCH3-phenyl
38h: Ar = 2,4,5-triOCH3-phenyl
38i: Ar = 2-F,4-OCH3-phenyl
38j: Ar = 3-CH3,4-OCH3-phenyl
38k: Ar = phenyl
38l: Ar = 2,5-diCF3-phenyl
38m: Ar = tiophen-2-yl




Fig. 11  General synthetic scheme to spiro[pyrrolidine-3,3′-oxindoles] 38a–n. Reagents and conditions: a 
ArCHO, NBS, water/tetrahydrofuran (THF), TFA (cat), 0 °C to r.t., yields: 45–94%
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growth of human breast cancer cell line MCF-7 by inducing apoptotic cell death at 
low micromolar  EC50 values (6.00, 4.01, and 3.53 µM, respectively). Chemical pro-
teomics indicated HDAC2 and PHB2 as potential targets of the spiro[pyrrolidine-
3,3-oxindoles] and molecular docking of the most active compound 38i with 
HDAC2 (PDB ID: 4LY1) confirmed probable binding interactions. Overall, based 
on their cytotoxic effects, compounds characterized by electron-donating or weak 
EWGs on the phenyl ring showed higher MCF-7 cell growth inhibition rates com-
pared with compounds bearing one or two strong EWGs.
3.3  Pyrrolidines Obtained via Aminocyclizations
Polyhydroxylated pyrrolidines, known as aza-sugars, are considered metabolically 
inert carbohydrates as they mimic the oxa-carbenium transition state from carbo-
hydrate processing enzymes. Due to their central role in different biological activi-
ties, they are emerging as attractive compounds for the treatment of cancer and 
metabolic diseases. In 2019, using the double reductive amination reaction, Guaz-

















































































































































Fig. 12  Blue panel Synthesis of diastereoisomers 41a,b and 42 obtained by reaction of 5,6-O-isopro-
pylidene-d-xylo-hexos-4-ulose 39 with benzylamine hydrochloride and l-phenylalanine methyl ester 
hydrochloride, respectively. Yellow panel Synthesis of final compounds 43a,b, 44a,b, 45, 46 and 47a,b. 
Reagents and conditions: a sodium cyanoborohydride  (NaBH3CN), methanol (MeOH); 60 °C, 24–48 h, 
yields: 37% (41a,b), 44% (42)
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the diastereoisomeric d-glucose and d-galactose series, as dual-target inhibitors of 
the enzymes α-glucosidase (AG) and aldose reductase (ALR2). Although AG repre-
sents the most important enzyme for controlling plasma sugar concentration, patho-
logical changes in nervous, renal, vascular, and ocular systems of diabetic patients 
are caused by activation of ALR2. Therefore, ideal antidiabetic agents should be 
able to simultaneously block the catalytic activity of AG and ALR2. Aminocycliza-
tion was conducted by reacting aldohexos-4-ulose derivatives 39 and 40 (Fig. 12) 
with amines, including benzylamine, benzhydrylamine, ammonia, l- or d-phenyla-
lanine methyl ester, and sodium cyanoborohydride  (NaBH3CN) as reducing agent, 
to obtain mixtures of d-glucose and d-galactose diastereoisomers. Among these, the 
authors isolated as pure compounds only diastereoisomers 41a,b and 42 (Fig. 12) 
obtained by reaction of 5,6-O-isopropylidene-d-xylo-hexos-4-ulose 39 with ben-
zylamine hydrochloride (for compounds 41a,b) and l-phenylalanine methyl ester 
hydrochloride (for compound 42). These three compounds were the starting mate-
rial for the synthesis of other derivatives. Thus, through hydrogenolysis, com-
pounds 43a,b were obtained and were, in turn, reacted with isobutyric anhydride 
to give compounds 44a,b. Finally, compounds 41b, 42, and 44a,b were subjected 
to hydrolysis to remove the 5,6-O-isopropylidene protecting group affording com-
pounds 45, 46, 47a,b, respectively, with enhanced hydrophilic character compared 
with the parent compounds. Among all, the d-galacto derivative 43b was able to 
reduce cell death and restore the physiological levels of oxidative stress, showing a 
percentage of enzyme inhibition at 100 μM of 57.1% and 30.2% against ALR2 and 
AG, respectively.
Recently, Li et al. [53] reported a series of (S)-pyrrolidines as CXCR4 chemokine 
receptor antagonists with antimetastatic activity. The synthesis of compounds 51a–f 
(Fig. 13) was carried out in a multi-step manner in which intermediate pyrrolidine 
derivatives 50 were obtained by reaction of pyridin-2-yl-4-oxobutanal derivatives 
48 with (R)-1-(4-methoxyphenyl)ethan-1-amine 49. Among all compounds gener-





















































Fig. 13  General synthetic scheme to pyrrolidines 51a–f. Reagents and conditions: a sodium triacetoxy-
borohydride [NaBH(OAc)3], DCM, − 70 °C to r.t., overnight, yields: 21–45%
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 (IC50 = 79  nM competitively displacing fluorescent 12G5 antibody). Conversely, 
by shifting the methyl group to other positions in the pyridine ring, the  IC50 value 
increased to 216, 278 and 2391 nM for compounds 51b, 51c and 51d, respectively. 
Another feature of compound 51a was its ability to inhibit CXCL12-induced cyto-
solic calcium flux  (IC50 = 0.25 nM). In order to mitigate the overall basicity of the 
compounds, which can lead to issues such as hERG potassium channel inhibition, 
as well as CYP enzyme inhibition and phospholipidosis, the authors introduced a 
fluorine atom (compound 51e) or a cyano group (compound 51f) at the  R1 position. 
However, this change greatly reduced the potency of compounds 51e and 51f, by 
4- and 7-fold, respectively. Interestingly, the antimetastatic behavior of compound 
51a was also shown in an in vivo tumor metastasis test conducted in mice, which 
received compound 51a intraperitoneally at a dose of 30 mg/kg.
3.4  Pyrrolidine‑2‑Ones Obtained by Cyclizations
The interest in polyhydroxylated pyrrolidines led Da Silva et al. [54] to search for 

















































Fig. 14  General synthetic schemes to polyhydroxylated pyrrolidines 54 and pyrrolidone 57. Reagents 
and conditions: a (1)  O3, MeOH, − 78  °C, 40  min; (2) DMS, 40  min, − 78  °C to r.t., not isolated; b 
[Zn(BH4)2], MeOH or DCM, − 20 °C, 2 h, yield: 74%; c TFA (2 equiv), DCM, 1 h, yield: 74%; d TBSCl, 
imidazole, DMF, 20 h, r.t., yield: 74%; e  BH3. DMS, THF, 4 h, r.t., yield: 60%; f tetra-n-butylammonium 
fluoride (TBAF), THF, 12 h, r.t., yield: 99%. g triethylamine (TEA), 1,4-dioxane, 5 h, under reflux, yield: 
77%
1 3
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54 (Fig. 14). Compound 54 is a polyhydroxylated pyrrolidine that is a more potent 
α-glycosidase (AG) inhibitor than its natural enantiomer compound 55 (Fig. 14). For 
this reason, compound 54 is reputed to be a potential starting point for new antidia-
betic and anticancer drugs. As shown in Fig. 14, the synthetic route proposed for the 
synthesis of 54 comprises six steps starting from a chiral Morita–Baylis–Hillman 
(MBH) adduct 53, which in turn was prepared from Garner’s aldehyde 52. Com-
pound 54 was obtained from an intermediate pyrrolidone, which was synthesized 
by a linear three-step reaction sequence involving ozonolysis of the double bond 
of the MBH adduct 53, followed by a stereoselective ketone reduction using zinc 
borohydride [Zn(BH4)2], concomitant N-double deprotection/O-deprotection with 
TFA, and a final amidation reaction (cyclization). Finally, the pyrrolidone interme-
diate was (1) silylated to decrease water solubility, (2) reduced with borane-dimethyl 
sulfide, and finally, (3) O-deprotected with tetra-n-butylammonium fluoride (TBAF) 
to afford compound 54.
By intermolecular cyclization reactions between 2-cyanoacetamide derivative 
56 and chloroacetonitrile, in the presence of triethylamine (TEA), under reflux in 
1,4-dioxane for 5  h, Debbabi et  al. [55] synthesized a series of N-ethyl-N-methyl 
benzenesulfonamides. Among these, derivative 57 (Fig.  14), characterized by a 
5-amino-3-cyano-2-oxopyrrolidine core, showed antiproliferative activity against 
MCF-7 cells in the micromolar range  (IC50 = 62.53 µM) and absence of cytotoxicity 
against normal fibroblasts of baby hamster kidney cell line (BHK). By docking stud-
ies, the activity of the compound was attributed to its binding to the dihydrofolate 
reductase (DHFR) (PDB ID: 4DFR).
3.5  Pyrrolidine‑2,5‑Diones Obtained by Cyclizations
Despite many years of research, it is still not clear how anticonvulsant drugs coun-
teract seizures, but it is known that many of them interact with voltage-gated sodium 
channels (VGSCs) and voltage-gated calcium channels (VDCCs) in the central 
nervous system (CNS). In agreement with previous studies in which pyrrolidine-
2,5-dione emerged as valuable scaffold in the treatment of epilepsy [56], in 2017, 
Rybka et  al. [57] synthesized a library of 1,3-disubstituted pyrrolidine-2,5-diones 
59a–p (Fig. 15), obtained via cyclocondensations of dicarboxylic acids 58 with the 
properly substituted 1-(2-aminoethyl)- and 1-(3-aminopropyl)-4-arylpiperazines, 
at 180 °C for 1.5 h. Derivatives 59a–p were administered intraperitoneally to mice 
and screened for their anticonvulsant activity by maximal electroshock (MES) and 
subcutaneous pentylenetetrazole (scPTZ) seizure tests in mice. Compounds 59j,n 
showed good activity in both tests (MES  ED50: 88.2 mg  kg−1 and 101.5 mg  kg−1, 
respectively; scPTZ  ED50: 65.7 mg   kg−1 and 59.7 mg   kg−1, respectively), indicat-
ing that they are able to prevent various kinds of seizures by blocking the sodium 
channel with higher affinity than phenytoin. SAR analysis revealed that the anticon-
vulsant activity is affected strongly by substituents at position 3 of the pyrrolidine-
2,5-dione scaffold. By scPTZ test, 3-benzhydryl 59a–d and 3-isopropyl 59e–h deriv-
atives showed the most favorable protection in the scPTZ test, whilst 3-methyl 59i–l 
and unsubstituted 59m–p derivatives were more active in the MES test. Derivatives 
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with a phenylpiperazine moiety bearing a 3-trifluoromethyl group were most active 
in the MES test, whilst 3,4-dichlorophenylpiperazines were active in both the MES 
and scPTZ tests. Finally, the increase in length of the alkyl chain resulted in deriva-
tives that displayed quick onset and long-lasting anticonvulsant activity. A similar 
class of anticonvulsant and antinociceptive agents was also synthesized recently by 
Góra et al. [58], who designed hybrid derivatives of pyrrolidine-2,5-dione with the 
thiophene ring, compounds 62a–g and 63a–h (Fig.  15). While compounds 62a–g 
were obtained by the reaction of 2-(3-methylthiophen-2-yl)succinic acid 60 with 
aminoalkylmorpholine or 1-(3-aminopropyl)-4-phenylpiperazine in one step, deriva-
tives 63a–h were obtained in two steps by the reaction of 2-(3-methylthiophen-2-yl)
succinic acid 60 with aminoacetic acid to give intermediates 61, which, in turn, 
underwent the coupling reaction. The best anticonvulsant activity was observed with 
compound 62b, which displayed an  ED50 value of 62.14 mg  kg−1 in the MES test, 
compared with references ethosuximide  (ED50 > 500  mg   kg−1) and valproic acid 
(VPA)  (ED50 252.7 mg  kg−1), and 75.59 mg  kg−1 in the psychomotor seizure (6 Hz) 




































63a:  X/R1 = O/-
63b: X/R1 = N/4-F-Ph
63c: X/R1 = N/3-CF3-Ph
63d: X/R1 = N/2-Cl-Ph
63e: X/R1 = N/3-Cl-Ph
63f: X/R1 = N/4-Cl-Ph
63g: X/R1 = N/2,3-diCl-Ph
63h: X/R1 = N/3,4-diCl-Ph
62a: R = -(CH2)-; X/R
1 = O/-
62b: R = -(CH2)2-; X/R
1 = O/-
62c: R = -(CH2)2-; X/R
1 = N/4-F-Ph
62d: R = -(CH2)2-; X/R
1 = N/3-CF3-Ph
62e: R = -(CH2)2-; X/R
1 = N/3-Cl-Ph
62f: R = -(CH2)2-; X/R
1 = N/4-Cl-Ph
















59a: R1 = -CH-diphenyl; R2 = 3-CF3; n = 2
59b: R1 = -CH-diphenyl; R2 = 3,4-diCl; n = 2
59c: R1 = -CH-diphenyl; R2 = 3-CF3; n = 3
59d: R1 = -CH-diphenyl; R2 = 3,4-diCl; n = 3
59e: R1 = -CH-diCH3; R
2 = 3-CF3; n = 2
59f: R1 = -CH-diCH3; R
2 = 3,4-diCl; n = 2
59g: R1 = -CH-diCH3; R
2 = 3-CF3; n = 3
59h: R1 = -CH-diCH3; R
2 = 3,4-diCl; n = 3
59i: R1 = CH3; R
2 = 3-CF3; n = 2
59j: R1 = CH3; R
2 = 3,4-diCl; n = 2
59k: R1 = CH3; R
2 = 3-CF3; n = 3 
59l: R1 = CH3; R
2 = 3,4-diCl; n = 3
59m: R1 = H; R2 = 3-CF3; n = 2
59n: R1 = H; R2 = 3,4-diCl; n = 2
59o: R1 = H; R2 = 3-CF3; n = 3
59p: R1 = H; R2 = 3,4-diCl; n = 3
58
Fig. 15  General synthetic routes to pyrrolidine-2,5-diones 59a–p, 62a–g, and 63a–h. Reagents and con-
ditions: a 180 °C, 1.5 h., yields: 60–82% (59a–p), 70% (61), 54–86 (62a–g)
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130.6  mg   kg−1). In addition, four of the tested compounds (62a,b,d,g) revealed 
peripheral analgesic activity in the writhing test. In particular, compound 62g was 
active at a dose of 30 mg/kg, similar to aspirin at the same dose. Compounds 62d 
and 62g also showed central analgesic activity in the hot-plate test at a dose of 
30 mg  kg−1. SAR analysis revealed that the acetamide moiety can extend anticon-
vulsant activity in both the MES and scPTZ tests.
Later, Obniska et al. [59] expanded the same class of pyrrolidine-2,5-diones by 
substituting the thiophene ring with an unsubstituted phenyl moiety. The new com-
pounds 66a–m (Fig. 16) were obtained by the condensation of 2-methyl-2-phenyl 








66a: R = H       
66b: R = 2-F
66c: R = 4-F
66d: R = 2-Cl
66e:R = 3-Cl
66f:R = 4-Cl


















69a: R,R1 = -Ph; R2 = 2-F
69b: R,R1 = -Ph; R2 = 4-F
69c: R,R1 = -Ph; R2 = 3-CF3
69d: R,R1 = -Ph; R2 = 2-Cl
69e: R,R1 = -Ph; R2 = 3-Cl
69f: R,R1 = -Ph; R2 = 4-Cl
69g: R,R1 = -Ph; R2 = 2,3-diCl





































69i: R = -C2H5; R
1 = -CH3; R
2 = 2-F
69j: R = -C2H5; R
1 = -CH3; R
2 = 4-F
69k: R = -C2H5; R
1 = -CH3; R
2 = 3-CF3
69l: R = -C2H5; R
1 = -CH3; R
2 = 2-Cl
69m: R = -C2H5; R
1 = -CH3; R
2 = 3-Cl
69n: R = -C2H5; R
1 = -CH3; R
2 = 4-Cl
69o: R = -C2H5; R
1 = -CH3; R
2 = 2,3-diCl
69p: R = -C2H5; R
1 = -CH3; R
2 = 3,4-diCl
Fig. 16  General synthetic routes to pyrrolidine-2,5-diones 66a–m and 69a–p. Reagents and conditions: a 
180 °C, 1 h, yields: 68% (65), 70% (68, R,  R1 = phenyl), 36% (68, R = methyl,  R1 = ethyl)
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65, at 180  °C for 1  h. This structural change did not improve the pharmacologi-
cal activity compared with the previously mentioned compound 62b. However, the 
activity of the most promising derivatives 66b,c,h was better than the reference 
VPA and ethosuximide, both in the MES test with  ED50 values of 78.3, 83.51 and 
97.67 mg   kg−1, respectively, and in the scPTZ test, in which only compound 66b 
was active  (ED50 114.15 mg  kg−1). Finally, in 2021, Góra et al. [60] studied the anti-
convulsant properties of two new series of pyrrolidine-2,5-dione-acetamides 69a–p 
(Fig. 16), exhibiting a benzhydryl or sec-butyl group in position 3 of the pyrrolidine 
ring. The compounds were synthesized via intermediates 68, which were obtained 
by the reaction of succinic acid derivatives 67 with aminoacetic acid at 180 °C for 
1 h. Among the tested compounds, derivative 69k showed the best  ED50 values of 
80.38 mg  kg−1 in the MES and 108.80 mg  kg−1 in the 6 Hz tests, emerging as more 
effective than VPA. Summarizing the SAR analysis of this class of compounds, the 
activity appeared to be influenced by the substituent at position 3 of the pyrrolidine-
2,5-dione ring, as well as the type of phenylpiperazine attached to the acetamide 
fragment. In particular, the non-aromatic substituent (sec-butyl) in position 3 of the 
pyrrolidine-2,5-dione ring and the 3-trifluoromethylphenylpiperazine fragment posi-
tively affect the anticonvulsant activity as for compound 69k. Slightly less active 
than compound 69k in the 6  Hz test was its 2-chlorophenylpiperazine analogue 
69l with a 1.2 fold higher  ED50 value. On the other hand, the introduction of the 
benzhydryl group in position 3 of the pyrrolidine-2,5-dione ring and a 4-chloro- 
or 2,3-dichlorophenylpiperazine fragment (compounds 69f and 69g) increased the 



















74a: X = N; R = -H
74b: X = -CH; R = -H
74c: X = -CH; R = -OCH3
74d: X = -CH; R = -Cl












71a: R = 4-C2H5-phenyl
71b: R = 2,4,6-triCH3-phenyl
71c: R = naphthalen-1-yl
71d: R = 4-CF3-quinolin-5-yl
71e: R = 4-benzoic acid
71f: R = 3-benzoic acid






Fig. 17  General synthesis of pyrrolidine-2,5-diones 71a–g and 74a–e. Reagents and conditions: a  SOCl2, 
under reflux, 5–8  h, yields: 83–96%; b OtBU-l-threonine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 
chloroform  (CHCl3), r.t., yields: 51.3–63.2%
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Pyrrolidine-2,5-dione is a versatile scaffold, as demonstrated by Oktay et al. 
[61] who prepared a series of 3-chloro-1-aryl pyrrolidine-2,5-diones evaluated 
for their inhibitory activity on the human physiologically relevant carbonic 
anhydrase (CA) isoenzymes hCA I and hCA II. Both isoenzymes are involved 
in several diseases, such as retinal and cerebral edema, glaucoma, and epi-
lepsy. Therefore, their inhibition could be useful to counteract these issues. 
The synthetic route to obtain the 3-chloro-N-aryl pyrrolidine-2,5-dione deriva-
tives 71a–g (Fig.  17) started with the reaction between maleic anhydride and 
aromatic amines, with consequent opening of the ring to yield (Z)-4-oxo-4-
(arylamino)but-2-enoic acid 70, which, in turn afforded compounds 71a–g by 
reaction with thionyl chloride  (SOCl2) under reflux. All 3-chloro-1-aryl pyrro-
lidine-2,5-diones, except compound 71e, were able to inhibit hCA I (Ki in the 
range of 23.27–36.83 nM) and hCA II (Ki in the range of 10.64 and 23.34 nM) 
with higher or comparable activity than the reference hCA inhibitor acetazola-
mide (AZA) (hCA I: Ki = 34.70  nM; hCA II: Ki = 31.93  nM). The most active 
compounds were derivatives 71d (hCA I: Ki = 23.27  nM) and 71c (hCA II: 
Ki = 10.64 nM), both decorated at the pyrrolidine-2,5-dione nitrogen atom with 
bicyclic scaffolds, such as quinoline and naphthalene.
As reported in the literature, cyclic imides, such as pyrrolidine-2,5-diones, 
possess interesting pharmacological properties due to the ability of the imide 
group to facilitate the crossing of biological membranes. Recently, Jan et  al. 
[62] synthesized a series of pyrrolidine-2,5-dione derivatives 74a–e (Fig. 17) as 
multitarget anti-inflammatory agents by applying a synthetic strategy based on 
Michael additions of ketones 73 to N-substituted maleimide 72, at room tem-
perature in the presence of OtBU-l-threonine and 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU), using a self-assembled three-component system as organocatalyst. 
Biological activity was determined by in vitro assays, such as cyclooxygenase-1 
(COX-1), cyclooxygenase-2 (COX-2), and 5-lipoxygenase (5-LOX), albu-
min denaturation and anti-protease assays, and in vivo in mice. In the in vitro 
assays, all compounds showed marked COX-2 inhibition compared with the ref-
erence diclofenac  (IC50 = 10.05  µM) with  IC50 values in the range of 0.98 and 
8.94  µM. The most potent compound was 74e, which showed selectivity for 
COX-2 over COX-1, with a selectivity index value (SI) [SI =  IC50 (COX-1)/IC50 
(COX-2)] of 31.5. In contrast, the SI values of compounds 74a–d were 4.88, 
11.5, 18.7 and 10.9, respectively. Furthermore, aryl ketone derivatives 74a and 
74e showed excellent inhibition of human 5-LOX with  IC50 values of 0.81 and 
0.86 µM, respectively, which were slightly higher than the standard drug zileu-
ton  (IC50 = 0.63 µM). Finally, compound 74a also induced albumin denaturation 
 (IC50 = 5.36) and protease inhibition  (IC50 = 13.39  µM). The in  vivo test with 
the most promising compounds 74a and 74e revealed anti-inflammatory activ-
ity, which was ascertained with various mediators like histamine, bradykinin, 
prostaglandin and leukotriene. In addition, the same compounds showed safety 
in an acute toxicity study, in which the lethal dose  (LD50) of both compounds 
in the experimental mice was approximately 1000  mg/kg. The SAR analysis 
revealed that the para-substituent on the phenyl ketone influences the biologi-
cal activity. However, the replacement of the aryl ketone at position 3 of the 
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pyrrolidine-2,5-dione nucleus with oxocycloalkyl/oxoalkyl groups (structure not 
shown) was detrimental to the anti-inflammatory properties.
3.6  Pyrrolizines Obtained by Cyclizations
In 2016, Gouda et al. [63] designed and synthetized a new series of pyrrolizine 
carboxamides 77–84 (Fig. 18) as dual cyclooxygenase (COX) and 5-LOX inhibi-
tors with safer gastric profile. Pyrrolizine 77 was synthesized via the intramo-
lecular cyclization of an intermediate obtained by reacting N-(4-bromophenyl)-
2-chloroacetamide 75 with 2-(pyrrolidin-2-ylidene)malononitrile 76 under reflux 
in acetone for 24 h, and was used as starting material for the synthesis of deriva-
tives 78–84. All pyrrolizines were assayed for anti-inflammatory activity and 
showed  IC50 values of 2.45–5.69 µM and 0.85–3.44 µM for COX-1 and COX-2, 
respectively. Furthermore, compound 77 exhibited higher anti-inflammatory and 
analgesic activities compared with ibuprofen. Upon  NH2-acylation, its analogues, 
such as the 2-chloroacetyl (82) and the benzoyl derivative (78) were obtained. 
Introduction of the 4-tolylsulfonyl moiety into compound 79 further improved 
both biological activities. Conversely, the hybrid compound 81, composed of the 
pyrrolizine precursor 77 and ibuprofen, did not show antiinflammatory activity 
and only a weak analgesic effect. 4-Methylpiperazine derivative 84, the diazepine 
derivative 83, and the dimer 80 showed lower anti-inflammatory and analgesic 
activities. Nevertheless, compounds 78 and 81 revealed better safety profiles than 
ibuprofen in acute ulcerogenicity and histopathological studies. Docking studies 















































78: R = -CO-phenyl
79: R = -SO2-4-CH3-phenyl
80: R = 77-CO-CO-77




Fig. 18  General synthetic scheme to pyrrolizine carboxamide derivatives 77–84. Reagents and condi-
tions: a  K2CO3, acetone, under reflux, 24 h, yields: 68% (77)
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3O8Y, 3V99) showed that compound 79 fits well into the active sites of COX-1 
and COX-2, whereas compound 79 exhibits the highest binding affinity for 
5-LOX.
4  Pyrrolidine Derivatives from Commercial Building Blocks
4.1  Pyrrolidines from Proline
The interest in the pyrrolidine nucleus as skeleton of molecules with biological 
potential is endorsed by its similarity to the non-essential l-proline amino acid, 
which is used to obtain molecules with a specific stereochemistry. In 2017, Pan-
nala et al. [64] developed a metal- and catalyst-free three-component decarboxyla-
tive coupling reaction of proline, aldehydes and 4-hydroxycarbazole to access pyr-
rolidinyl-carbazole derivatives 85a–p (Fig. 19) with antiproliferative and antioxidant 
activities. The antiproliferative activity was evaluated by in vitro assays on three dif-
ferent cancer cell lines (MCF-7, MDA-MB-231, and lung cancer cells A549) and 
the results were compared with those obtained with the positive control doxorubicin. 
Overall, compounds 85b,c,k,p showed the best cytotoxic activity against MCF-7 







85a: R = phenyl
85b: R = 4-F-phenyl
85c: R = 4-Cl-phenyl
85d: R = 4-Br-phenyl
85e: R = 4-CN-phenyl
85f: R = 4-CF3-phenyl
85g: R = 3-OCH3-phenyl
85h: R = 3-OCH2CH3,4-OH-phenyl
85i: R = 3,4-diOCH3-phenyl
85j: R = 4-benzyloxy,3-OCH3-phenyl
85k: R = 2,4,6-triF-phenyl
85l: R = 2,4,6-triOCH3-phenyl
85m: R = pyridin-2-yl
85n: R = pyridin-3-yl
85o: R = napht-1-yl



















86a: R = piperidin-1-yl
86b: R = 4-C2H5-piperazin-1-yl
86c: R = 4-benzyl-piperazin-1-yl












88a: R1 = phenyl; R2 = -CH2-phenyl; R
3 = -NHSO2-phenyl
88b: R1 = phenyl; R2 = -CH2-phenyl; R
3 = -NHSO2-(4-CH3)-phenyl
88c: R1 = phenyl; R2 = -CH2-phenyl; R
3 = -NHSO2-(3NO2,4Cl)-phenyl
88d: R1 = phenyl; R2 = -CH2-(4-Br)-phenyl; R
3 = -NHSO2-phenyl
88e: R1 = phenyl; R2 = -CH2-(4-Br)-phenyl; R
3 = -NHSO2-(4-CH3)-phenyl
88f: R1 = phenyl; R2 = -CH2-(4-Br)-phenyl; R
3 = -NHSO2-(3NO2,4Cl)-phenyl
88g: R1 = phenyl; R2 = -CH2-(4-Br)-phenyl; R
3 = -NHSO2-(4-NO2)-phenyl
88h: R1 = phenyl; R2 = -CH2-(4-Br)-phenyl; R
3 = -NHSO2-(4-Cl)-phenyl
88i: R1 = phenyl; R2 = -CH2-1H-indole-3-yl; R
3 =  -NHSO2-phenyl
88j: R1 = phenyl; R2 = -CH2-1H-indole-3-yl; R
3 =  -NHSO2-(3NO2,4Cl)-phenyl
88k: R1 = 4-CH3-phenyl; R
2 = -CH2-phenyl; R
3 = -NHSO2-phenyl
88l: R1 = 4-CH3-phenyl; R
2 = -CH2-phenyl; R
3 = -NHSO2-(4-CH3)-phenyl
88m: R1 = 4-CH3-phenyl; R
2 = -CH2-phenyl; R
3 = -NHSO2-(3NO2,4Cl)-phenyl
88n: R1 = 4-CH3-phenyl; R
2 = -CH2-(4-Br)-phenyl; R
3 = -NHSO2-(3NO2,4Cl)-phenyl
88o: R1 = 4-Cl-phenyl; R2 = -CH2-(4-Br)-phenyl; R
3 = -NHSO2-(3NO2,4Cl)-phenyl
88q: R1 = phenyl; R2 = -CH2-(4-OH)-phenyl; R
3 = -NHSO2-(3NO2,4Cl)-phenyl
Fig. 19  Molecular structures of pyrrolidinyl-carbazole derivatives 85a–p, pyrrolidine-2-carbonitriles 
86a–d, Mcl-1 inhibitor 87, and pyrrolidine-1-carboxylates 88a–p 
 Topics in Current Chemistry          (2021) 379:34 
1 3
  34  Page 30 of 46
of A549 with an  IC50 value of 15.7  µM. Furthermore, compounds 85b,f,h,j,m 
showed higher radical scavenging abilities than ascorbic acid  (IC50 40.9 µM), with 
the best results displayed by compound 85 h  (IC50 = 27 µM) due to the presence of 
the hydroxy group on the phenyl ring. Docking analysis in the colchicine binding 
site (PDB ID: 1SA0) indicated that a methoxy-benzyloxy moiety (85j) and a trifluo-
romethyl group (85f) on the phenyl ring participate in hydrophobic binding interac-
tions with several amino acid residues. Halogenated compounds 85b–d,k displayed 
similar binding modes in the tubulin active site. Finally, a bulky naphthyl ring (85o) 
reduced the binding affinity.
The use of proline for the synthesis of pyrrolidine derivatives was also a strategic 
path for Nabil Aboul-Enein et  al. [65], who synthesized a small class of antidia-
betic compounds. The (S)-1-[(cyclohexylmethyl)glycyl]pyrrolidine-2-carbonitriles 
86a–d obtained (Fig. 19) were biologically evaluated for inhibitory activity toward 
dipeptidyl peptidase-4 (DPP4), a serine exopeptidase belonging to the S9B protein 
family, which cuts X-proline dipeptides from the N-terminus of polypeptides, such 
as chemokines, neuropeptides, and peptide hormones. As DPP4 is known to inac-
tivate the incretin glucagon-like peptide-1 (GLP-1), the discovery of new DPP4 
inhibitors is considered an indirect approach to increase GLP-1 levels and thus to 
manage diabetes mellitus type 2. The starting point for the synthesis of derivatives 
86a–d was (2S)-1-(chloroacetyl)pyrrolidine-2-carbonitrile, which could be obtained 
from S-proline via a chloroacetylation followed by an amidation of its carboxylate 
group and a final dehydration. The ability of compounds 86a–d to inhibit the DPP4 
enzyme was studied in diabetic mice that received the compounds orally at a dose 
of 100 mg/kg and the results were compared with those of the control group that 
received vildagliptin at the same dose. Serum DPP4 inhibition was evaluated 3 h 
after treatment. Among all, compounds 86b,c inhibited DPP4 activity better (153% 
and 138%, respectively) than the control group (114%). In contrast, replacement 
of the piperazine ring with piperidine (86a) or (4-methoxybenzyl)piperazine (86d) 
reduced DPP4 inhibition to 85% and 105%, respectively. Docking studies confirmed 
a good binding affinity of compounds 86b,c in the active site of DPP4 (PDB ID: 
3W2T) in agreement with their anti-diabetic activity.
Starting from (2S,4R)-4-hydroxyproline, Wan et al. [66] designed and synthesized 
a new series of pyrrolidine derivatives based on compound 87, which was described 
as potent inhibitor of myeloid cell leukemia-1 (Mcl-1) protein (Ki = 8.4  µM) 
(Fig. 19). Using a fluorescence polarization assay (FPA), these authors observed that 
the most potent compounds 88a–p were characterized by phenyl groups at  R1, aro-
matic or heteroaromatic rings at  R2, and different benzenesulfonamides at  R3. Com-
pounds 88c and 88f showed the best binding affinities towards Mcl-1, with Ki values 
of 0.94 and 0.53 µM, respectively, slightly higher than the positive control gossypol 
(Ki = 0.39 µM) but very much lower than compound 87. The replacement of phenyl 
or 4-bromophenyl at  R2 with 3-indolyl and p-hydroxyphenyl (88i,j,p) was unfavora-
ble for the biological activity. Finally, the replacement of the benzensulfonamide 
moiety with a hydroxy group and the introduction of linear chains or substituted 
phenyls instead of the 4-bromobenzyl group (structures not shown) resulted in the 
loss of binding affinity toward the Mcl-1 protein (Ki > 10 µM). Moreover, compound 
88f exhibited good antiproliferative activities against MDA-MB-231, PC-3 (prostate 
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cell cancer), and K562 (chronic myeloid leukaemia) cell lines with  IC50 values of 
13.6, 10.7, and 23.0 µM, respectively.
In 2020, Gerokonstantis et  al. [67] synthesized compounds 89a–e and 90 
(Fig. 20), which are potent inhibitors of autotaxin (ATX), a glycoprotein respon-
sible for the hydrolysis of lysophosphatidylcholine (LPC) into bioactive lipid 
lysophosphatidic acid (LPA), whose upregulation is involved in pathological 
inflammatory conditions. The main scaffolds of the new derivatives were the nat-
ural amino acid S-proline, the naturally derived S-pyroglutamic acid ((2S)-5-ox-
opyrrolidine-2-carboxylic acid), and their enantiomers. In both cases, the new 
derivatives possess a benzyl type substituent at the pyrrolidine nitrogen, while the 
carboxylic group at position 5 is coupled to side chain via an amide bond contain-
ing a benzyl-ether type substituent, which bears carboxylate, methyl ester, sul-
fonamide, boronic ester, imidazole, hydroxamate, tetrazole, triazol, pyridine and 
boronic acid moieties in para-position (structures not shown). The in vitro assay 
showed that the pyroglutamic acid derivatives, including hydroxamic acid 89a 
 (IC50 700 nM) and boronic acid derivatives 89b  (IC50 50 nM), 89c  (IC50 120 nM), 






















91a: R = -H; R1 = -H
91b: R = -H; R1 = -NO2
91c: R = -H; R1 = -Cl
91d: R = -ethyl; R1 = -H
91e: R = -ethyl; R1 = -NO2
91f: R = -ethyl; R1 = -Cl
91g: R = -propyl; R1 = -H
91h: R = -propyl; R1 = -NO2
91i: R = -phenyl; R1 = -H
91j: R = -phenyl; R1 = -NO2
91k: R = -phenyl; R1 = -Cl
91a-k




89b: R = -H; R1 = B
O
O
89c: R = -F; R1 = B
O
O
89d: R = -F; R1 = -COOH
89e: R = -F; R1 = -B(OH)2
Fig. 20  Molecular structures of pyroglutamic acid derivatives 89a–e and 90 and N-(2′-nitrophenyl)pyrro-
lidine-2-carboxamides 91a–k 
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the ATX enzyme, whereas only one out of six compounds—the carboxylic acid 
derivative 89d—was the least active  (IC50 800 nM).
Antimicrobial peptides (AMPs) are small peptides with a wide range of inhibi-
tory effects against bacteria and other pathogens. Pyrrhocoricin, apidaecin and 
drosocin are some examples of proline-rich antibacterial peptide family members 
able to bind the bacterial DnaK protein. In 2020, Odusami et  al. [68] reported 
the synthesis of novel N-(2′-nitrophenyl)pyrrolidine-2-carboxamides 91a–k 
(Fig. 20) with the aim of searching for amino acid analogues with antibacterial 
properties capable of mimicking antimicrobial peptides. The main structural fea-
tures of compounds 91a–k were the simultaneous presence of (1) a hydropho-
bic group provided by the phenyl ring, and (2) a cationic charge given by the 
amino group after its protonation, (3) different N′-substituents introduced to study 
the effect of conformational flexibility on the antimicrobial activity. The activ-
ity was evaluated both against Gram-positive [Bacillus subtilis (ATCC 19659), 
Enterococcus faecalis (ATCC 14506), Mycobacterium smegmatis (ATCC 14468), 
Staphylococcus epidermidis (ATCC 12228) and Staphylococcus aureus (ATCC 
25923)] and Gram-negative [Enterobacter cloacae (ATCC 13047), Escherichia 
coli (ATCC 25922), Proteus vulgaris (ATCC 33420), Klebsiella oxytoca (ATCC 
8724) and Proteus mirabilis (ATCC 7002)] bacterial strains, and the results were 
compared with those of reference compounds streptomycin and nalidixic acid. 
As assessed by the minimum inhibitory concentration (MIC) values, all the car-
boxamides 91a–k were more potent against S. aureus and E. cloacae than the 
standard streptomycin (256  µg/ml and > 512  µg/ml, respectively), with com-
pounds 91b (15.6 µg/ml), 91c and 91k (62.5 µg/ml for both) being most potent 
against S. aureus, and compounds 91c (62.5 µg/ml) and 91j (31.3 µg/ml) being 
most potent against E. cloacae. Furthermore, the MIC values of compounds 
91a–k were lower than those found with nalidixic acid (≥ 500 µg/ml) against E. 
faecalis, M. smegmatis, E. coli, and P. vulgaris (MIC ≤ 250 µg/ml). Conversely, 
for other strains, the MICs of the carboxamides were higher than the ones of the 
reference compounds. SAR investigation showed that, in consideration of the N′-
substituents, antibacterial activity increased in the order: N′-Et (91d–f) < N′-H 
(91a–c) < N′-Pr (91g,h) < N′-Ph (91i–k), whereas with the 4′-phenyl substitu-
ents, the activity increased in the order: 4′-PhH (91a,d,g,i) < 4′-PhCl (91c and 
91f) < 4′-PhNO2 (91b,e,h) except for the N′-phenyl carboxamides 91i–91k, where 
91k (4′-Cl) > 91j (4′-NO2) > 91i (4′-H).
4.2  Derivatives from Other Preformed Pyrrolidine Scaffolds
Given the interest of the scientific community in the pyrrolidine nucleus, many 
chemical industries have synthesized variously substituted pyrrolidines as build-
ing blocks for new drugs. Among these, pyrrolidine, pyrrolidin-2-one, pyrrolidine-
2,5-dione, and prolinol scaffolds are very useful preformed rings for the synthesis of 
new bioactive compounds.
Beta-secretase 1 (BACE1) is the enzyme responsible for the proteolytic pro-
cessing of the amyloid precursor protein (APP), which leads to the generation of 
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amyloid-β (Aβ) peptides. The aggregation of Aβ in the brain of patients is respon-
sible for the onset of Alzheimer’s disease (AD). Therefore, the development of 
treatments towards BACE1 could be a good strategy to fight this devastating neuro-
degenerative disease. In 2016, De Tran et al. [69] synthesized a library of (3S,4S)-
4-aminopyrrolidine-3-ol derivatives 92a,b (Fig. 21) as potential anti-AD agents with 
a target selectivity toward BACE1. An in vitro inhibition assay of BACE1 showed 
that compound 92a was the most active, with an  IC50 value of 0.05 µM. However, 
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93-94a: R = -H
93-94b: R = -2,3-diOCH3
93-94c: R = -3,4,5-triOCH3
93-94d: R = -4-OH
93-94e: R = -2-OH
93-94f: R = -2,4-diOH
93-94g: R = -3-CH3
93-94h: R = -4-CH3
93-94i: R = -4-NO2
93-94j: R = -4-CF3
93-94k: R = -4-OCF3
93-94l: R = -4-Cl
93-94m: R = -4-F
93-94n: R = -4-Br
93-94o: R = -2,4-diF
92a: X = CO
92b: X = CH2
Fig. 21  Molecular structures of pyrrolidine derivatives 92a,b, Schiff bases 93a–o and their reduced 
counterparts 94a-o, benzenesulfonylpyrrolidines 95a–d, and pyrrolidine-based 3-deoxysphingomyelins 
96, 97a,b, 98, 99a,b 
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92b, the inhibition of BACE1 was approximately two times lower  (IC50 = 0.12 µM). 
Unexpectedly, the opposite was observed in the cell-based assay ,where compound 
92b was more effective than compound 92a, most probably due to a difference in 
cell permeability  (IC50 values 1.7 versus 40  µM, respectively). Boc-deprotected 
derivatives having the pyrrolidine nitrogen atom unsubstituted or substituted with 
alkyl, acyl or sulfonyl groups were less active (structures not shown). A molecular 
docking study confirmed interactions with the BACE1 active site.
Novel compounds for the treatment of Alzheimer’s disease were also investi-
gated by Choubey et al. [70], who synthesized multitargeted molecular hybrids of 
N-benzyl pyrrolidine derivatives, like imines 93a–o and their reduced counterpart 
94a–o (Fig. 21). All compounds were studied for their inhibitory activity towards 
of cholinesterases (AChE and BChE) and BACE-1 in order to evaluate their mul-
titarget profile. Overall, derivatives 94a–o inhibited both cholinesterases as well as 
BACE-1 with greater potency than Schiff bases 93a–o. SAR studies revealed that 
electron donating groups (EDGs) at the terminal phenyl ring elicit less potency 
with respect to acetylcholinesterase (AChE) inhibition than EWGs. Thus, deriv-
atives bearing an EWG exhibited  IC50 values of less than 1  µM, as observed for 
compounds 94k (0.058 µM) and 94o (0.069 µM), which were found to be almost 
as active as the reference donepezil (0.042 µM). A similar trend was observed for 
butyrylcholinesterase (BChE) inhibition. All the Schiff bases, with the exception of 
the compound 93j containing a 4-CF3 group, showed a moderate inhibitory effect, 
whereas, among compounds 94a–o, substitution with EWGs gave excellent BACE-1 
inhibitors. Only in a few cases, such as for compounds 93j,k,o, and 94c,d,f,i, was 
the intended multitarget profile not observed.
Anticancer activity of pyrrolidine derivatives was studied by Bashandy et  al. 
[71], who synthetized a new series of compounds characterized by the presence of 
a benzenesulfonylpyrrolidine moiety bearing a variously substituted 1,3-thiazole 
ring in position 4 of the phenyl ring. All compounds were tested for their in vitro 
antiproliferative activity against MCF-7 cells. Only a few compounds, namely 
95a (benzo[4,5]imidazo[1,2-a]pyridine), 95b ((4-oxo-3-phenyl-1,3-thiazolidin-
2-ylidene)ethanenitrile), 95c ((4-fluorophenyl)-acrylonitrile), and 95d (benzo[f]
chromen-3-one) (Fig. 21), exhibited a slight improved activity compared to doxo-
rubicin  (IC50 = 68.6  μM), with  IC50 values of 49.11, 48.01, 49.78 and 49.27  μM, 
respectively. In addition, molecular docking studies confirmed their ability to bind 
the DHFR active site (PDB ID: 4DFR).
In 2019, Hassan et  al. [72] synthesized a series of pyrrolidine-based 3-deox-
ysphingomyelin analogues carrying various acyl chains (palmitoyl, palmitoleoyl, 
oleoyl, erucoyl, linoleoyl, and α-linolenoyl) at the pyrrolidine nitrogen atom and 
evaluated the compounds as antitumor agents against a panel of cancer cell lines 
including breast, non-small-cell lung, liver, and skin cancers. The most promising 
compounds were characterized by erucoyl (96, 97b, 99b) or palmitoyl (97a, 98, 
99a) chains (Fig. 21). The best results were obtained for MCF-7 cells, which were 
more sensitive to the treatment with compounds 96, 97b, and 99b, eliciting  GI50 
values at the micromolar level (15.7–24.8 µM). This effect was also confirmed in 
their study on the inhibition of Akt phosphorylation. In fact, compounds 97a, 98, 
and 99a bearing identical acyl chains but exhibiting different stereochemistry, were 
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equally active, with  GI50 values of 21.1, 26.4, and 32.5 µM, respectively, confirming 
the stereochemistry as irrelevant for activity. Molecular docking studies established 
that the interaction with Akt (PDB ID: 3O96) may be the predominant mechanism 
of action of the 3-deoxysphingomyelin analogues tested.
In 2018, Zhang et  al. [73] synthesized new hybrid benzofuroxan-based pyrro-
lidine hydroxamates carrying on the pyrrolidine nitrogen atom two different sub-
stituents: a 3-phenoxybenzenesulfonyl (100a,b) or a (3,4-dimethoxyphenyl)prop-2-
enoly (101a,b) moiety (Fig.  22). All compounds elicited antiproliferative activity 
against several tumor cell lines, including A549, ES-2 (ovarian clear carcinoma 
cell), HeLa (cervix carcinoma), K562, MCF-7, and MDA-MB-231  (IC50 values 
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Fig. 22  Molecular structures of hybrid benzofuroxan-based pyrrolidine hydroxamates 100a,b and 
101a,b, pyrrolidine benzonitriles 102a–c, hybrid pyrrolidine derivatives 103, 104a,b, 105, 106, and pyr-
rolidine amides 107, 108, 109a,b, 110, 111 
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anticancer activity was ascribed to the inhibition of matrix metalloproteinases 2 and 
9 (MMP-2 and MMP-9), as indicated by the reduced proteolytic activity after their 
isolation from treated cells. Among the phenoxybenzenesulfonamides, the 5-ben-
zofuroxan 100a showed higher MMP-2 and -9 inhibitory activity  (IC50 values of 
102 and 162 nM, respectively) than the 4-benzofuroxan analog 100b  (IC50 values of 
182 and 242 nM, respectively), whereas the (3,4-dimethoxyphenyl)prop-2-enamide-
5-benzofuroxan (101a) and the 4-benzofuroxan (101b) were less effective  (IC50 val-
ues of 345–524 nM). Docking studies carried out in the active site of MMP-2 (PDB 
ID: 1HOV) with compound 101a highlighted the ability of the hydroxamate group 
to chelate the catalytic zinc ion and both arylsulfonyl and benzofuroxan groups to 
create hydrogen bonds with amino acid residues.
Although polyhydroxylated pyrrolidines are important scaffolds of molecules for 
the treatment of metabolic diseases [52, 54], hydroxy groups could be subject to 
oxidation and conjugation reactions that would make the molecules metabolically 
unstable. In this regards, with the aim of modifying the pharmacokinetic profile, 
Asano et  al. [74] synthesized 4-(pyrrolidin-1-yl)benzonitrile derivatives 102a–c 
(Fig.  22) as selective androgen receptor modulators (SARMs) by optimizing the 
structure of previously reported 1-(4-cyano-1-naphthyl)-2,3-disubstituted pyrroli-
dine derivatives [75]. In particular, they introduced a methyl group at C-3 of the 
pyrrolidine ring that, due to its steric hindrance, should prevent metabolic instabil-
ity, conferring better pharmacokinetic (PK) profiles than the parent 3-hydroxy com-
pounds. Compounds 102b,c had low cLogP values (< 3), showed better metabolic 
stability, and retained potent androgen receptor (AR) agonistic activity. In addi-
tion, 2-chlorobenzonitrile 102b and 3-fluoro-2-methylbenzonitrile 102c derivatives 
showed good bioavailability values (53.4 and 46.3%, respectively) and strong ana-
bolic activity in levator ani muscle (> 300%), which was dose-dependent as dem-
onstrated by in vivo studies on rats after oral administration. The X-ray co-crystal 
structure of 102c bound to the AR LBD (PDB: 5T8J) highlighted a binding mode 
almost identical to that of the previously studied (2S,3S)-2-methyl-3-hydroxylpyrro-
lidine-2-chloro-3-methylbenzonitrile [75].
In 2018, Kaur et  al. [76] designed and synthesized a library of hybrid mol-
ecules by combining triazine-indole with morpholine/piperidine/pyrrolidine and 
pyrazole/pyrimidine/oxindole moieties, as novel anti-inflammatory agents. All 
compounds were tested for inhibition of COX-1 and COX-2 and the results were 
compared with that of diclofenac, a COXs non-selective inhibitor, and celecoxib, 
a potent and selective COX-2 inhibitor. Of all compounds tested, pyrrolidine 
derivatives 103,104a,b,105,106 (Fig.  22) inhibited COX-2 with  IC50 values in 
the range of 1–8 µM. The most potent was the compound 106, characterized by a 
1-(3-chlorophenyl)-3-methyl-2-pyrazolin-5-one moiety, with an  IC50 value of 1 µM. 
The SI ratio  (IC50 COX-1/IC50 COX-2) revealed compound 106 as selective for 
COX-2 (SI = 7), compared with compounds 106,104a,b, and 105, which were non-
selective. In addition, docking studies highlighted a well-docked pose in the COX-2 
active site showing H-bond and hydrophobic interactions. Surprisingly, compound 
106 also decreased formalin-induced analgesia by 69%.
N-Acylethanolamine acid amidase (NAAA) is a lysosomal hydrolase that cata-
lyzes the degradation of N-acylethanolamines into fatty acids and ethanolamine in 
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animal tissues. Its inhibition is a therapeutic tool in several pathophysiological con-
ditions, such as inflammation and immune disorders, as well as pain. In 2019, Zhou 
et al. [77] synthesized a new series of pyrrolidine amide derivatives as antiinflamma-
tory agents and tested their selectivity towards NAAA and fatty acid amide hydro-
lase (FAAH), using rat NAAA (rNAAA) and rat FAAH (rFAAH) as animal model. 
The starting idea was to modify the linker chain and the terminal phenyl group 
of compounds 107 and 108 (Fig.  22), which were previously described as potent 
NAAA inhibitors  (IC50 = 12.8 and 2.1  µM, respectively). The most active com-
pounds were 109a,  (IC50 = 0.5 µM) 109b  (IC50 = 0.7 µM), 110  (IC50 = 0.48 µM), and 
111  (IC50 = 1.5 µM) (Fig.  22) showing good NAAA inhibitory effects. Conversely, 
no relevant activity towards FAAH was found. Studies on the chemical space on 
compounds 107 and 108 indicated that the activity was lost upon substitution with 
 CH3, Cl, and F in position 2 of the terminal phenyl ring of parent 107. Instead, an 
improvement of activity was observed upon introduction of the same substituents 
at positions 3 or 4  (IC50 3.7–9.6 µM), except for the 4-Cl derivative  (IC50 34.5 µM) 
(structures not shown). The same modifications on the terminal phenyl ring of com-
pound 108 were detrimental for activity, most probably due to the conformationally 
restricted chain. Isosteric replacements of the distal phenyl ring with aromatic moie-
ties such as 2-pyridyl, 3-pyridyl, 2-thienyl, and 3-thienyl, did not improve potency. 
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Fig. 23  Molecular structures of triazine-pyrrolidine-2-thiones 112a,b and pyrrolidin-2-ones 113a,b, pyr-
rolidin-2-ones 114a–e, and pyrrolidin-2-ones 115a–o 
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and 109b, highlighting that (hetero)aromatic rings are less tolerated in the hydro-
phobic pocket of NAAA than aliphatic rings. Regarding the carbon chain between 
the pyrrolidine and the phenyl ring, the authors showed that flexible linkers led to 
a progressive increase in potency, except for compound 111, which was well suited 
to the hydrophobic pocket of NAAA. Molecular docking studies (PDB ID:6DY2) 
suggested that 111 may inhibit NAAA via a reversible and competitive inhibition 
mechanism.
As analogues of isoxazole compounds, in 2019 Lucescu et al. [78] synthesized 
and tested triazine-pyrrolidine-2-thiones 112a,b (Fig.  23) on the human protein 
farnesyltransferase (FTase). This protein catalyses the addition of a C15-farnesyl 
lipid group to the cysteine residue located in the carboxy-terminal tetrapeptide motif 
of a variety of important substrate proteins playing an important role in malignant 
transformations including proliferation, apoptosis, angiogenesis, and metastasis. 
Compound 112a showed good inhibitory activity toward the FTase enzyme with an 
 IC50 of 3.82  µM, which was approximately 11-fold lower than that of compound 
112b  (IC50 = 41.06  µM), highlighting the importance of the EWG on the phenyl 
ring. Interestingly, these two derivatives showed much better activity compared with 
the analogue in which pyrrolidine was replaced by the aromatic oxazole ring (struc-
ture not shown). In addition, the replacement of pyrrolidine-2-thione with pyrroli-
din-2-one 113a,b (Fig. 23) did not affect activity toward the FTase protein.
The pyrrolidine-2-one scaffold is a structural feature recurrent in antitumor 
agents, as demonstrated by Kumar et al. [79] who synthesized the novel derivatives 
114a–e (Fig.  23) by the reaction of substituted salicylaldehydes and 2-(2-oxopyr-
rolidin-1-yl)acetamide, leading to the respective Schiff base intermediates which 
were, in turn, reduced with sodium borohydride. Among all, compounds 114d and 
114e showed the highest growth inhibition percentage against CCRF-CEM (acute 
lymphocytic leukemia) (114d = 73.15%) and NCI-H522 (non-small cell lung can-
cer) (114e = 41.8%) of the National Cancer Institute (NCI) panel. SAR analysis 
revealed that EWGs at positions 3 or 5 of the phenyl ring were unfavorable for anti-
proliferative activity compared with electron-donating methoxy groups. Hydroxy 
group introduction at position 2 (114d and 114e) led to an increase in antiprolif-
erative activity compared with compounds 114b and 114c. Docking analyses sug-
gested binding to the podophyllotoxin pocket of the protein gamma tubulin (PDB 
ID: 1SA1) as a potential mechanism of action underlying the anticancer activity.
The versatility of the pyrrolidine-2-one scaffold was demonstrated by Rezai et al. 
[80], who synthesized novel N-benzyl-2-pyrrolidone derivatives 115a–o (Fig.  23) 
as antioxidants and inhibitors of AChE and BChE. AChE is an ubiquitous enzyme 
of the serine hydrolases class responsible for hydrolyzing the neurotransmitter ace-
tylcholine, together with the homologous BChE. AD is the most common form 
of dementia, characterized by loss of short-term memory, spatial disorientation, 
progressive loss of cognitive function, decreased intellect, and some other minor 
expressions. A common feature of the AD is the presence of AChE, which is usually 
related to the Aβ plaques and neurofibrillary tangles in the patient’s brain. Recent 
findings suggested that both Aβ and abnormally hyperphosphorylated tau protein 
(P-tau) may influence the AChE expression with the development of a vicious cycle 
of Aβ and P-tau dysregulation. In this context, AChE and BChE inhibitors can 
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improve the cholinergic transmission, but with modest and temporary therapeutic 
effects. All compounds synthesized by the authors were able to inhibit the AChE 











116a: R = -4-CH
3
; R1 = -H; R2 = -H
116b: R = -4-CH
3
; R1 = -F; R2 = -H
116c: R = -4-CH
3
; R1 = -F; R2 = -F
116d: R = -2-furyl in place of phenyl; R1 = -F; R2 = -F
116e: R = -2-Cl ; R1 = -H; R2 = -H
116f: R = -H; R1 = -H; R2 = -H
116g: R = -4-F ; R1 = -H; R2 = -H
116h: R = -H ; R1 = -F; R2 = -H
116i: R = -thiophen-2-yl in place of phenyl ; R1 = -H; R2 = -H
116j: R = -2-furyl in place of phenyl ; R1 = -H; R2 = -H
116k: R = -2-furyl in place of phenyl ; R1 = -F; R2 = -H
116l: R = -3,4-diOCH
3
; R1 = -F; R2 = -F



























(R)-121a: R1 = -NH
2
(S)-122a: R1 = -NH
2
(R)-121b: R1 = -H

















(R)-119a: R1 = -NH
2
(S)-120a: R1 = -NH
2
(R)-119b: R1 = -H

























125a: R = NH
2
125b: R = -H
b,a221-121b,a021-911
Fig. 24  Molecular structures of hybrid pyrrolidine-2,5-diones 116a–m, 2-(hydroxymethyl)pyrrolidines 
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 Topics in Current Chemistry          (2021) 379:34 
1 3
  34  Page 40 of 46
16.36 nM. The most powerful AChE inhibitor was compound 115f with a Ki value 
of 2.60 nM. Furthermore, all compounds inhibited BChE with Ki values in the range 
of 13.10 and 54.47  nM. Measuring the DPPH radical scavenging activity, com-
pounds 115b,c,l–o showed interesting antioxidant activity with half maximal radical 
scavenging concentrations  (IC50 µg/ml) in the range of 4.71 and 53.30. The radical 
scavenger activity is affected by the phenolic fraction and varies according to the 
number and position of the hydroxy groups.
To escape the problem of drug resistance, Tilekar et al. [81] recently published 
new pyrazoline-substituted pyrrolidine-2,5-dione hybrids 116a–m (Fig.  24), with 
anticancer activity against MCF7, HT29, and K562 cancer cells. Compounds 
116b,f,g, showed nanomolar activity against MCF7 with  IC50 values in the range 
of 0.42 and 0.78 µM. Compounds 116b and 116m showed also activity in the sub-
micromolar range against HT29 cells  (IC50 0.92 µM and 0.39 µM, respectively). The 
cytotoxicity assay against K562 revealed that compounds 116a and 116g  (IC50 24.74 
and 31.56 µM, respectively) were more potent than the reference compound piogl-
itazone  (IC50 40.3 µM). Further studies with compound 116b demonstrated its abil-
ity to reduce the cell population in the G2/M phase and increase the cell population 
in the G0/G1 phase, as well as inhibition of the anti-apoptotic protein Bcl-2 in a 
dose-dependent manner.
To obtain potent dual sphingosine kinase 1/2 (SphK1/SphK2) inhibitors, Li et al. 
[82] synthesized a series of 2-(hydroxymethyl)pyrrolidines, based on SAR investi-
gation of potent and selective inhibitors previously reported in the literature (com-
pound 117, SphK1-selective inhibitor) (Fig. 24). These enzymes are involved in the 
production of sphingosine 1-phosphate (S1P) from sphingosine and ATP, in a sig-
nalling pathway that is involved in cancer progression and immune cell chemiotaxis. 
While the 2-(hydroxymethyl)pyrrolidine scaffold is essential for hydrogen bonding 
with Asp178 in the binding pocket of SphK1, alteration of the aryl sulphonyl moi-
ety changes the selectivity for SphK1 and SphK2. In this regard, the authors intro-
duced various lipophilic substituents (i.e., alkyl, aryl, alkoxy, etc.) to the scaffold 
of compound 117 in place of the aryl sulphonyl moiety to mimic the sphingosine 
substrate of SphK1 and SphK2. The dodecyl analogue 118 proved to be the most 
potent dual SphK1/SphK2 inhibitor (SphK1 Ki = 0.679 μM, SphK2 Ki = 0.951 μM) 
compared with derivatives with a shorter alkyl tail. On the other hand, the diaryl 
ether, alkoxy, alkenyl, alkynyl analogues (structures not shown) showed no improve-
ment in biological activity. Molecular docking studies highlighted that compound 
118 fitted in the Sph binding pocket of SphK1 establishing hydrogen bonding of 
the 2-(hydroxymethyl)pyrrolidine moiety. Specifically, (1) the primary alcohol 
hydrogen bonded with Ser168 and (2) the tertiary nitrogen hydrogen bonded with 
Asp178. Similarly, hydrogen bonds between the pyrrolidine nitrogen and Asp308 
as well as the hydroxyl group and Ser298 were observed in the homology model of 
SphK2 docked with 118. The aliphatic dodecyl alkyl tail of compound 118 acquires 
a specific “J-shape”, generating hydrophobic interactions within the binding pocket 
of the enzyme.
Recently, Frydrych et  al. [83] used commercially available d- and l-prolinol as 
the starting material for the synthesis of novel antimalarial agents, yielding new chi-
ral compounds in which a pyrrolidine ring is incorporated in the linker connecting the 
1 3
Topics in Current Chemistry          (2021) 379:34  Page 41 of 46    34 
purine base to the phosphonate group(s) (119a,b and 120a,b) (Fig. 24). Compounds 
119a,b and 120a,b were evaluated as inhibitors of the plasmodial hypoxanthine-gua-
nine-(xanthine)-phosphoribosyltransferase [HG(X)PRT] of Plasmodium falciparum, 
P. vivax (HGPRT) and human HGPRT, and the results were compared with those of 
the previously published inhibitors 123, 124, 125a,b (Fig. 24). The biological results 
did not show an improvement in activity over compounds 123, 124, 125a,b. In fact, 
the new nucleotide analogues had Ki values in the range between 9 and > 50 mM for 
human HGPRT, 5–44 mM for PfHGXPRT and between 20 and > 50 mM for PvHG-
PRT, despite the increased flexibility achieved by the implementation of a  CH2 group 
between the nucleobase and the pyrrolidine ring, which allows a free rotation. The 
same results were obtained when replacing the pyrrolidine nucleus with a six mem-
bered-ring, such as piperidine or piperazine (structures not showed). However, the 
phosphoramidate prodrugs 121a,b and 122a,b (Fig. 24), exhibited good antimalarial 
activity in a P. falciparum-infected human erythrocyte assay. In particular, the bisphos-
phoramidate prodrug 122a was potent  (IC50 = 2.5 µM) against the chloroquine resistant 
P. falciparum W2 strain, with low cytotoxicity in human hepatocellular liver carcinoma 
(HepG2) and normal human dermal fibroblasts (NHDF) cell lines at a concentration of 
100 µM.
5  Concluding Remarks
The present review is intended to provide significant support to medicinal chemists 
in the discovery of new biologically active pyrrolidine derivatives, providing a gen-
eral overview of recent research concerning this scaffold, offering quick identification 
of the best synthetic route to apply. From this work, pyrrolidine emerges as a versa-
tile scaffold found in molecules that exhibit a broad spectrum of biological activities. 
Pyrrolidines are useful to build compounds for fighting cancer and microbial infec-
tions, for metabolic diseases, as agents active in the CNS and for neurodegenerative 
diseases and immune disorders. Since three-dimensionality is an essential element 
of ligand–target interactions, the stereocenters present in pyrrolidine scaffolds would 
allow medicinal chemists to develop molecules with the most suitable configurations 
to fit into the ligand binding site of a target protein. In order to discover structurally 
novel compounds, the scaffold hopping strategy could be applied to the pyrrolidine 
core while maintaining its stereochemistry, together with exploration of the SAR of 
the most active pyrrolidine derivatives. We believe that the chemical versatility of the 
pyrrolidine nucleus and its ability to generate structural diversity could be essential to 
establish the clinical success of new bioactive molecules.
Funding Open access funding provided by Università degli Studi di Palermo within the CRUI-CARE 
Agreement. No funding was received to assist with the preparation of this manuscript.
Declarations 
Conflict of Interest The authors declare that they have no known competing financial interests or personal 
relationships that could have appeared to influence the work reported in this paper.
 Topics in Current Chemistry          (2021) 379:34 
1 3
  34  Page 42 of 46
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, 
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Com-
mons licence, and indicate if changes were made. The images or other third party material in this article 
are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is 
not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission 
directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen 
ses/ by/4. 0/.
References
 1. Raimondi MV, Presentato A, Li Petri G et al (2020) New synthetic nitro-pyrrolomycins as prom-
ising antibacterial and anticancer agents. Antibiotics 9:292. https:// doi. org/ 10. 3390/ antib iotic 
s9060 292
 2. Raimondi MV, Listro R, Cusimano MG et  al (2019) Pyrrolomycins as antimicrobial agents. 
Microwave-assisted organic synthesis and insights into their antimicrobial mechanism of action. 
Bioorg Med Chem 27:721–728. https:// doi. org/ 10. 1016/j. bmc. 2019. 01. 010
 3. Spanò V, Rocca R, Barreca M et  al (2020) Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d][1,2]oxazoles, 
a new class of antimitotic agents active against multiple malignant cell types. J Med Chem 
63:12023–12042. https:// doi. org/ 10. 1021/ acs. jmedc hem. 0c013 15
 4. Cascioferro S, Maggio B, Raffa D et al (2016) A new class of phenylhydrazinylidene derivatives 
as inhibitors of Staphylococcus aureus biofilm formation. Med Chem Res 25:870–878. https:// 
doi. org/ 10. 1007/ s00044- 016- 1535-9
 5. Whatmore JL, Swann E, Barraja P et al (2002) Comparative study of isoflavone, quinoxaline and 
oxindole families of anti-angiogenic agents. Angiogenesis 5:45–51. https:// doi. org/ 10. 1023/a: 
10215 28628 524
 6. Jampilek J (2019) Heterocycles in medicinal chemistry. Molecules. https:// doi. org/ 10. 3390/ 
molec ules2 42138 39
 7. Gomtsyan A (2012) Heterocycles in drugs and drug discovery. Chem Heterocycl Comp 48:7–10. 
https:// doi. org/ 10. 1007/ s10593- 012- 0960-z
 8. Brown DG, Boström J (2016) Analysis of past and present synthetic methodologies on medicinal 
chemistry: where have all the new reactions gone? J Med Chem 59:4443–4458. https:// doi. org/ 
10. 1021/ acs. jmedc hem. 5b014 09
 9. Everett SA, Naylor MA, Barraja P et  al (2001) Controlling the rates of reductively-activated 
elimination from the (indol-3-yl)methyl position of indolequinones. J Chem Soc Perkin Trans 
2:843–860. https:// doi. org/ 10. 1039/ B0096 52K
 10. Clemons PA, Wilson JA, Dančík V et al (2011) Quantifying structure and performance diversity 
for sets of small molecules comprising small-molecule screening collections. Proc Natl Acad Sci 
USA 108:6817–6822. https:// doi. org/ 10. 1073/ pnas. 10150 24108
 11. Lovering F, Bikker J, Humblet C (2009) Escape from flatland: increasing saturation as an 
approach to improving clinical success. J Med Chem 52:6752–6756. https:// doi. org/ 10. 1021/ 
jm901 241e
 12. Aldeghi M, Malhotra S, Selwood DL, Chan AWE (2014) Two- and three-dimensional rings in 
drugs. Chem Biol Drug Des 83:450–461. https:// doi. org/ 10. 1111/ cbdd. 12260
 13. Ritchie TJ, Macdonald SJF, Peace S et al (2012) The developability of heteroaromatic and heteroa-
liphatic rings—do some have a better pedigree as potential drug molecules than others? Med Chem 
Commun 3:1062–1069. https:// doi. org/ 10. 1039/ C2MD2 0111A
 14. Goldberg FW, Kettle JG, Kogej T et  al (2015) Designing novel building blocks is an overlooked 
strategy to improve compound quality. Drug Discov Today 20:11–17. https:// doi. org/ 10. 1016/j. 
drudis. 2014. 09. 023
 15. Tajabadi FM, Campitelli MR, Quinn RJ (2013) Scaffold flatness: reversing the trend. Springer Sci 
Rev 1:141–151. https:// doi. org/ 10. 1007/ s40362- 013- 0014-7
 16. Maier ME (2015) Design and synthesis of analogues of natural products. Org Biomol Chem 
13:5302–5343. https:// doi. org/ 10. 1039/ C5OB0 0169B
1 3
Topics in Current Chemistry          (2021) 379:34  Page 43 of 46    34 
 17. Liu XC, Lai D, Liu QZ et al (2016) Bioactivities of a new pyrrolidine alkaloid from the root barks 
of Orixa japonica. Molecules. https:// doi. org/ 10. 3390/ molec ules2 11216 65
 18. Carroll FI (2009) Epibatidine analogs synthesized for characterization of nicotinic pharmacoph-
ores—a review. Heterocycles 79:99–120
 19. Islam MT, Mubarak MS (2020) Pyrrolidine alkaloids and their promises in pharmacotherapy. Adv 
Tradit Med 20:13–22. https:// doi. org/ 10. 1007/ s13596- 019- 00419-4
 20. Bhat C, Tilve SG (2014) Recent advances in the synthesis of naturally occurring pyrrolidines, pyr-
rolizidines and indolizidine alkaloids using proline as a unique chiral synthon. RSC Adv 4:5405–
5452. https:// doi. org/ 10. 1039/ C3RA4 4193H
 21. Vitaku E, Smith DT, Njardarson JT (2014) Analysis of the structural diversity, substitution patterns, 
and frequency of nitrogen heterocycles among US FDA Approved Pharmaceuticals. J Med Chem 
57:10257–10274. https:// doi. org/ 10. 1021/ jm501 100b
 22. Dalko PI, Moisan L (2004) In the golden age of organocatalysis. Angew Chem Int Ed 43:5138–
5175. https:// doi. org/ 10. 1002/ anie. 20040 0650
 23. Higashiyama K, Inoue H, Takahashi H (1994) Diastereoselective addition of chiral imines 
and 1,3-oxazolidines with grignard reagents; asymmetric synthesis of (R)-2-aryl- and (R, R)-
2,5-bis(aryl)pyrrolidines. Tetrahedron 50:1083–1092. https:// doi. org/ 10. 1016/ S0040- 4020(01) 
80819-X
 24. Llopis S, García T, Cantín Á et al (2018) Chiral hybrid materials based on pyrrolidine building units 
to perform asymmetric Michael additions with high stereocontrol. Catal Sci Technol 8:5835–5847. 
https:// doi. org/ 10. 1039/ C8CY0 1650J
 25. Henary M, Kananda C, Rotolo L et  al (2020) Benefits and applications of microwave-assisted 
synthesis of nitrogen containing heterocycles in medicinal chemistry. RSC Adv 10:14170–14197. 
https:// doi. org/ 10. 1039/ D0RA0 1378A
 26. Li Petri G, Spanò V, Spatola R et al (2020) Bioactive pyrrole-based compounds with target selectiv-
ity. Eur J Med Chem 208:112783. https:// doi. org/ 10. 1016/j. ejmech. 2020. 112783
 27. Cascioferro S, Raimondi MV, Cusimano MG et al (2015) Pharmaceutical potential of synthetic and 
natural pyrrolomycins. Molecules 20:21658–21671. https:// doi. org/ 10. 3390/ molec ules2 01219 797
 28. Raimondi MV, Schillaci D, Petruso S (2007) Synthesis and anti-staphylococcal activity of new halo-
genated pyrroles related to Pyrrolomycins F. J Heterocycl Chem 44:1407–1411. https:// doi. org/ 10. 
1002/ jhet. 55704 40626
 29. Adrio J, Carretero JC (2019) Stereochemical diversity in pyrrolidine synthesis by catalytic asym-
metric 1,3-dipolar cycloaddition of azomethine ylides. Chem Commun 55:11979–11991. https:// 
doi. org/ 10. 1039/ C9CC0 5238K
 30. Biswas AK, Johnson DG (2012) Transcriptional and nontranscriptional functions of E2F1 in 
response to DNA damage. Cancer Res 72:13–17. https:// doi. org/ 10. 1158/ 0008- 5472. CAN- 11- 2196
 31. Gupta MR, Thakur K, Khare NK (2018) L-Proline/CeCl3·7H2O-NaI mediated stereoselective syn-
thesis of α-2-deoxy glycosides from glucal. Carbohydr Res 457:51–55. https:// doi. org/ 10. 1016/j. 
carres. 2018. 01. 003
 32. Brooks WH, Guida WC, Daniel KG (2011) The significance of chirality in drug design and develop-
ment. Curr Top Med Chem 11:760–770. https:// doi. org/ 10. 2174/ 15680 26117 95165 098
 33. Kunitski M, Riehn C, Matylitsky V et  al (2010) Pseudorotation in pyrrolidine: rotational coher-
ence spectroscopy and ab initio calculations of a large amplitude intramolecular motion. Phys Chem 
Chem Phys 12:72–81. https:// doi. org/ 10. 1039/ B9173 62E
 34. Galloway WRJD, Isidro-Llobet A, Spring DR (2010) Diversity-oriented synthesis as a tool for the 
discovery of novel biologically active small molecules. Nat Commun 1:80. https:// doi. org/ 10. 1038/ 
ncomm s1081
 35. Kumar A, Gupta G, Srivastava S (2010) Diversity oriented synthesis of pyrrolidines via natural car-
bohydrate solid acid catalyst. J Comb Chem 12:458–462. https:// doi. org/ 10. 1021/ cc100 007a
 36. Koskinen AMP, Helaja J, Kumpulainen ETT et al (2005) Locked conformations for proline pyrroli-
dine ring: synthesis and conformational analysis of cis- and trans-4-tert-butylprolines. J Org Chem 
70:6447–6453. https:// doi. org/ 10. 1021/ jo050 838a
 37. Jurica EA, Wu X, Williams KN et al (2017) Discovery of pyrrolidine-containing GPR40 agonists: 
stereochemistry effects a change in binding mode. J Med Chem 60:1417–1431. https:// doi. org/ 10. 
1021/ acs. jmedc hem. 6b015 59
 38. Luxenburger A, Schmidt D, Ianes C et al (2019) Design, synthesis and biological evaluation of isox-
azole-based CK1 inhibitors modified with chiral pyrrolidine scaffolds. Molecules 24:873. https:// 
doi. org/ 10. 3390/ molec ules2 40508 73
 Topics in Current Chemistry          (2021) 379:34 
1 3
  34  Page 44 of 46
 39. Fanning SW, Hodges-Gallagher L, Myles DC et al (2018) Specific stereochemistry of OP-1074 dis-
rupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity. Nat Commun 9:2368. 
https:// doi. org/ 10. 1038/ s41467- 018- 04413-3
 40. Jiang B, Duan JJ-W, Stachura S et al (2020) Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-
(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonists. 
Bioorg Med Chem Lett 30:127392. https:// doi. org/ 10. 1016/j. bmcl. 2020. 127392
 41. An F, Maji B, Min E et al (2020) Basicities and nucleophilicities of pyrrolidines and imidazolidi-
nones used as organocatalysts. J Am Chem Soc 142:1526–1547. https:// doi. org/ 10. 1021/ jacs. 9b118 
77
 42. Breugst M, Reissig H-U (2020) The Huisgen reaction: milestones of the 1,3-dipolar cycloaddition. 
Angew Chem Int Ed 59:12293–12307. https:// doi. org/ 10. 1002/ anie. 20200 3115
 43. Maiuolo L, Algieri V, Olivito F, De Nino A (2020) Recent developments on 1,3-dipolar cycloaddi-
tion reactions by catalysis in green solvents. Catalysts 10:65. https:// doi. org/ 10. 3390/ catal 10010 065
 44. Coldham I, Hufton R (2005) Intramolecular dipolar cycloaddition reactions of azomethine ylides. 
Chem Rev 105:2765–2810. https:// doi. org/ 10. 1021/ cr040 004c
 45. Min R, Wu W, Wang M et al (2019) Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrro-
lidine-3-yl)-1H-benzo[d]imidazole-4-carboxamide: a potent poly(ADP-ribose) polymerase (PARP) 
inhibitor for treatment of cancer. Molecules 24:1901. https:// doi. org/ 10. 3390/ molec ules2 41019 01
 46. Wang Y, Zhao H, Brewer JT et al (2018) De Novo design, synthesis, and biological evaluation of 
3,4-disubstituted pyrrolidine sulfonamides as potent and selective glycine transporter 1 competitive 
inhibitors. J Med Chem 61:7486–7502. https:// doi. org/ 10. 1021/ acs. jmedc hem. 8b002 95
 47. Zhang H, Ding CZ, Lai Z et al (2015) Synthesis and biological evaluation of novel pyrrolidine acid 
analogs as potent dual PPARα/γ agonists. Bioorg Med Chem Lett 25:1196–1205. https:// doi. org/ 10. 
1016/j. bmcl. 2015. 01. 066
 48. Periyasami G, Kamalraj S, Padmanaban R et al (2019) Glucosamine-6-phosphate synthase inhibit-
ing C3-β-cholesterol tethered spiro heterocyclic conjugates: synthesis and their insight of DFT and 
docking study. Bioorg Chem 88:102920. https:// doi. org/ 10. 1016/j. bioorg. 2019. 102920
 49. Shyamsivappan S, Saravanan A, Vivek R et al (2020) Novel phenyl and thiophene dispiro indeno-
quinoxaline pyrrolidine quinolones induced apoptosis via G1/S and G2/M phase cell cycle arrest in 
MCF-7 cells. New J Chem 44:15031–15045. https:// doi. org/ 10. 1039/ D0NJ0 2588G
 50. Benabdallah M, Talhi O, Nouali F et  al (2018) Advances in spirocyclic hybrids: chemistry and 
medicinal actions. Curr Med Chem 25:3748–3767. https:// doi. org/ 10. 2174/ 09298 67325 66618 03091 
24821
 51. Hati S, Tripathy S, Dutta PK et al (2016) Spiro[pyrrolidine-3, 3′-oxindole] as potent anti-breast can-
cer compounds: their design, synthesis, biological evaluation and cellular target identification. Sci 
Rep 6:1–10. https:// doi. org/ 10. 1038/ srep3 2213
 52. Guazzelli L, D’Andrea F, Sartini S et al (2019) Synthesis and investigation of polyhydroxylated pyr-
rolidine derivatives as novel chemotypes showing dual activity as glucosidase and aldose reductase 
inhibitors. Bioorg Chem 92:103298. https:// doi. org/ 10. 1016/j. bioorg. 2019. 103298
 53. Li Z, Wang X, Lin Y et al (2020) Design, synthesis, and evaluation of pyrrolidine based CXCR4 
antagonists with in vivo anti-tumor metastatic activity. Eur J Med Chem 205:112537. https:// doi. 
org/ 10. 1016/j. ejmech. 2020. 112537
 54. da Silva EC, Yamakawa NCG, Santos AAD, Coelho F (2017) Short and diastereoselective total syn-
thesis of the polyhydroxylated pyrrolidine LAB-1: a potent α-glycosidase inhibitor. Synth 49:4869–
4875. https:// doi. org/ 10. 1055/s- 0036- 15907 99
 55. Debbabi KF, Al-Harbi SA, Al-Saidi HM et  al (2016) Study of reactivity of cyanoacetohydrazo-
noethyl-N-ethyl-N-methyl benzenesulfonamide: preparation of novel anticancer and antimicrobial 
active heterocyclic benzenesulfonamide derivatives and their molecular docking against dihydro-
folate reductase. J Enzym Inhib Med Ch 31:7–19. https:// doi. org/ 10. 1080/ 14756 366. 2016. 12178 51
 56. Rybka S, Obniska J, Rapacz A et al (2017) Synthesis and evaluation of anticonvulsant properties of 
new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl-, 3-isopropyl, and 3-ben-
zhydryl analogs. Bioorg Med Chem Lett 27:1412–1415. https:// doi. org/ 10. 1016/j. bmcl. 2017. 02. 002
 57. Rybka S, Obniska J, Żmudzki P et al (2017) Synthesis and determination of lipophilicity, anticon-
vulsant activity, and preliminary safety of 3-substituted and 3-unsubstituted N-[(4-arylpiperazin-
1-yl)alkyl]pyrrolidine-2,5-dione derivatives. ChemMedChem 12:1848–1856. https:// doi. org/ 10. 
1002/ cmdc. 20170 0539
1 3
Topics in Current Chemistry          (2021) 379:34  Page 45 of 46    34 
 58. Góra M, Czopek A, Rapacz A et al (2020) Synthesis, anticonvulsant and antinociceptive activity of 
new hybrid compounds: derivatives of 3-(3-methylthiophen-2-yl)-pyrrolidine-2,5-dione. Int J Mol 
Sci 21:5750. https:// doi. org/ 10. 3390/ ijms2 11657 50
 59. Obniska J, Góra M, Rapacz A et al (2021) Synthesis, anticonvulsant, and antinociceptive activity of 
new 3-(3-methyl-2,5-dioxo-3-phenylpyrrolidin-1-yl)propanamides and 3-phenyl-butanamides. Arch 
Pharm (Weinheim) 354:e2000225. https:// doi. org/ 10. 1002/ ardp. 20200 0225
 60. Góra M, Czopek A, Rapacz A et al (2021) Design, synthesis and biological activity of new amides 
derived from 3-benzhydryl and 3-sec-butyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid. ChemMedChem 
16:1619–1630. https:// doi. org/ 10. 1002/ cmdc. 20200 1007
 61. Oktay K, Kose L, Şendil K et al (2017) Synthesis of 3-chloro-1-substituted aryl pyrrolidine-2,5-di-
one derivatives: discovery of potent human carbonic anhydrase inhibitors. Med Chem Res. https:// 
doi. org/ 10. 1007/ s00044- 017- 1865-2
 62. Jan MS, Ahmad S, Hussain F et al (2020) Design, synthesis, in-vitro, in-vivo and in-silico stud-
ies of pyrrolidine-2,5-dione derivatives as multitarget anti-inflammatory agents. Eur J Med 
Chem 186:111863. https:// doi. org/ 10. 1016/j. ejmech. 2019. 111863
 63. Gouda AM, Ali HI, Almalki WH et  al (2016) Design, synthesis, and biological evaluation of 
some novel pyrrolizine derivatives as COX inhibitors with anti-inflammatory/analgesic activities 
and low ulcerogenic liability. Molecules 21:201. https:// doi. org/ 10. 3390/ molec ules2 10202 01
 64. Pannala P, Reddy P, Misra S et al (2017) Synthesis, molecular docking, in vitro antiproliferative 
and antioxidant activity of novel pyrrolidinyl-carbazole derivatives. Curr Org Synth 14:1172–
1179. https:// doi. org/ 10. 2174/ 15701 79414 66617 06061 20934
 65. Aboul-Enein M, El-Azzouny AAE-S, Saleh OA et  al (2016) Synthesis, bio-evaluation and 
molecular modeling studies of (2S)-1-[({[1-substituted cyclohexyl] methyl} amino) acetyl] pyr-
rolidine-2-carbonitriles for their DPP-4 inhibiting activity. Int J Pharm Sci Rev Res 39:230–240 
(scopus ID: 19700188319)
 66. Wan Y, Wang J, Sun F et al (2015) Design, synthesis and preliminary biological studies of pyr-
rolidine derivatives as Mcl-1 inhibitors. Bioorg Med Chem 23:7685–7693. https:// doi. org/ 10. 
1016/j. bmc. 2015. 11. 014
 67. Gerokonstantis DT, Nikolaou A, Magkrioti C et al (2020) Synthesis of novel 2-pyrrolidinone and 
pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme. Bioorg 
Med Chem 28:115216. https:// doi. org/ 10. 1016/j. bmc. 2019. 115216
 68. Odusami JA, Ikhile MI, Izunobi JU et  al (2020) Synthesis of substituted N-(2′-nitrophenyl)
pyrrolidine-2-carboxamides towards the design of proline-rich antimicrobial peptide mimics to 
eliminate bacterial resistance to antibiotics. Bioorg Chem 105:104340. https:// doi. org/ 10. 1016/j. 
bioorg. 2020. 104340
 69. De Tran Q, Bepary S, Lee GH et al (2016) Synthesis of (3S,4S)-4-aminopyrrolidine-3-ol deriva-
tives and biological evaluation for their BACE1 inhibitory activities. Bioorg Med Chem Lett 
26:51–54. https:// doi. org/ 10. 1016/j. bmcl. 2015. 11. 033
 70. Choubey PK, Tripathi A, Sharma P, Shrivastava SK (2020) Design, synthesis, and multitargeted 
profiling of N-benzylpyrrolidine derivatives for the treatment of Alzheimer’s disease. Bioorg 
Med Chem 28:115721. https:// doi. org/ 10. 1016/j. bmc. 2020. 115721
 71. Bashandy M, El-Gilil S (2016) Synthesis, molecular docking and antihuman breast cancer 
activities of novel thiazolyl acetonitriles and thiazolyl acrylonitriles and their derivatives con-
taining benzenesulfonylpyrrolidine moiety. Heterocycles 92:431–469. https:// doi. org/ 10. 3987/ 
COM- 15- 13384
 72. Hassan AHE, Park HR, Yoon YM et al (2019) Antiproliferative 3-deoxysphingomyelin analogs: 
design, synthesis, biological evaluation and molecular docking of pyrrolidine-based 3-deox-
ysphingomyelin analogs as anticancer agents. Bioorg Chem 84:444–455. https:// doi. org/ 10. 
1016/j. bioorg. 2018. 11. 040
 73. Zhang H, Wang X, Mao J et al (2018) Synthesis and biological evaluation of novel benzofuro-
xan-based pyrrolidine hydroxamates as matrix metalloproteinase inhibitors with nitric oxide 
releasing activity. Bioorg Med Chem 26:4363–4374. https:// doi. org/ 10. 1016/j. bmc. 2018. 06. 023
 74. Asano M, Hitaka T, Imada T et al (2017) Synthesis and biological evaluation of novel selective 
androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile 
derivatives. Bioorg Med Chem Lett 27:1897–1901. https:// doi. org/ 10. 1016/j. bmcl. 2017. 03. 038
 75. Aikawa K, Miyawaki T, Hitaka T et al (2015) Synthesis and biological evaluation of novel selec-
tive androgen receptor modulators (SARMs). Part I. Bioorg Med Chem 23:2568–2578. https:// 
doi. org/ 10. 1016/j. bmc. 2015. 03. 032
 Topics in Current Chemistry          (2021) 379:34 
1 3
  34  Page 46 of 46
 76. Kaur S, Kumari P, Singh G et  al (2018) Design and synthesis of aza-/oxa heterocycle-based 
conjugates as novel anti-inflammatory agents targeting cyclooxygenase-2. ACS Omega 3:5825–
5845. https:// doi. org/ 10. 1021/ acsom ega. 8b004 45
 77. Zhou P, Xiang L, Zhao D et  al (2019) Synthesis, biological evaluation, and structure activity 
relationship (SAR) study of pyrrolidine amide derivatives as N-acylethanolamine acid amidase 
(NAAA) inhibitors. Med Chem Commun 10:252–262. https:// doi. org/ 10. 1039/ C8MD0 0432C
 78. Lucescu L, Ghinet A, Shova S et al (2019) Exploring isoxazoles and pyrrolidinones decorated 
with the 4,6-dimethoxy-1,3,5-triazine unit as human farnesyltransferase inhibitors. Arch Pharm 
352:1800227. https:// doi. org/ 10. 1002/ ardp. 20180 0227
 79. Kumar A, Singh UK, Muzaffar F et al (2018) Design, synthesis and anti-proliferative activity of 
noval 1,2,4-triazine and pyrrolidin-2-one derivatives. Der Pharma Chemica 10(1):124–131
 80. Rezai M, Bayrak Ç, Taslimi P et al (2018) The first synthesis and antioxidant and anticholinergic 
activities of 1-(4,5-dihydroxybenzyl)pyrrolidin-2-one derivative bromophenols including natural 
products. Turk J Chem 42:808–825. https:// doi. org/ 10. 3906/ kim- 1709- 34
 81. Tilekar K, Upadhyay N, Meyer-Almes F-J et al (2020) Synthesis and biological evaluation of pyra-
zoline and pyrrolidine-2,5-dione hybrids as potential antitumor agents. ChemMedChem 15:1813–
1825. https:// doi. org/ 10. 1002/ cmdc. 20200 0458
 82. Li H, Sibley CD, Kharel Y et al (2021) Lipophilic tail modifications of 2-(hydroxymethyl)pyrro-
lidine scaffold reveal dual sphingosine kinase 1 and 2 inhibitors. Bioorg Med Chem 30:115941. 
https:// doi. org/ 10. 1016/j. bmc. 2020. 115941
 83. Frydrych J, Keough DT, Chavchich M et  al (2021) Nucleotide analogues containing a pyrro-
lidine, piperidine or piperazine ring: synthesis and evaluation of inhibition of plasmodial and 
human 6-oxopurine phosphoribosyltransferases and in vitro antimalarial activity. Eur J Med Chem 
219:113416. https:// doi. org/ 10. 1016/j. ejmech. 2021. 113416
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published 
maps and institutional affiliations.
Authors and Affiliations
Giovanna Li Petri1 · Maria Valeria Raimondi1  · Virginia Spanò1 · Ralph Holl2 · 
Paola Barraja1 · Alessandra Montalbano1
1 Department of Biological, Chemical and Pharmaceutical Sciences and Technologies 
(STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy
2 Department of Chemistry, Institute of Organic Chemistry, University of Hamburg, 
Martin-Luther-King-Platz 6, 20146 Hamburg, Germany
